{"content":"<li class=\"n-box-item date-title\" data-end=\"1506657599\" data-start=\"1506571200\" data-txt=\"Monday, December 23, 2019\">Thursday, September 28, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3298325\" data-ts=\"1506639519\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBS\" target=\"_blank\">CBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298325-cbs-may-sell-television-city-studio-for-hundreds-of-millions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CBS may sell Television City studio for hundreds of millions</a></h4><ul>   <li>CBS (<a href=\"http://seekingalpha.com/symbol/CBS\" target=\"_blank\">CBS</a> <font color='red'>-2.2%</font>) is considering <a href=\"https://www.bizjournals.com/losangeles/news/2017/09/28/cbs-mulling-sale-of-television-city-studios-in-los.html\" target=\"_blank\">selling its famed Television City studios</a> in Los Angeles, a sale that could draw $500M-$750M ... or as much as $900M, based on a prized location.</li>    <li>The network has reportedly been interviewing more than five brokerages over the sale but has narrowed the search to a final two.</li>    <li>The company apparently began marketing the property after unsolicited offers came in.</li>    <li>It's not clear whether CBS would sell the property outright or pursue a sale-leaseback or ground lease; Television City has about 1M square feet of studio and office space, including eight stages.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298325\" data-linked=\"CBS may sell Television City studio for hundreds of millions\" data-tweet=\"$CBS $VIAC - CBS may sell Television City studio for hundreds of millions https://seekingalpha.com/news/3298325-cbs-may-sell-television-city-studio-for-hundreds-of-millions?source=tweet\" data-url=\"https://seekingalpha.com/news/3298325-cbs-may-sell-television-city-studio-for-hundreds-of-millions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298320\" data-ts=\"1506637336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATHM\" target=\"_blank\">ATHM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298320-autohome-closes-down-4_3-cfo-president-exit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Autohome closes down 4.3% as CFO, president exit</a></h4><ul>   <li>Autohome (NYSE:<a href='https://seekingalpha.com/symbol/ATHM' title='Autohome Inc.'>ATHM</a>) regained some ground from its worst drops today, finishing <font color='red'>down 4.3%</font>, after its executive office was <a href=\"https://seekingalpha.com/pr/16953535-autohome-inc-announces-management-change\" target=\"_blank\">roiled by heavy changes</a>.</li>    <li>Chief Financial Officer Julian Jiun-lang Wang resigned, to be replaced by Jun Zou. And President Yan Kang resigned his post with no successor.</li>    <li>Both men resigned from the board, which leaves the body with seven members.</li>    <li>The resignations weren't tied to any disagreement with the company, Autohome said.</li>    <li>Zou was most recently chief financial officer at iDreamSky and has more than 23 years of experience in financial management and capital markets.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298320\" data-linked=\"Autohome closes down 4.3% as CFO, president exit\" data-tweet=\"$ATHM - Autohome closes down 4.3% as CFO, president exit https://seekingalpha.com/news/3298320-autohome-closes-down-4_3-cfo-president-exit?source=tweet\" data-url=\"https://seekingalpha.com/news/3298320-autohome-closes-down-4_3-cfo-president-exit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298319\" data-ts=\"1506636486\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PARR\" target=\"_blank\">PARR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298319-par-pacific-photronics-set-to-join-s-and-p-smallcap-600\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Par Pacific, Photronics set to join S&amp;P SmallCap 600</a></h4><ul>     <li>Par Pacific (NYSEMKT:<a href='https://seekingalpha.com/symbol/PARR' title='Par Pacific Holdings, Inc.'>PARR</a>) <font color='green'>+4%</font>&nbsp;AH and Photronics (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAB' title='Photronics, Inc.'>PLAB</a>) <font color='green'>+4.8%</font> on news that the companies <a href=\"https://www.spice-indices.com/idpfiles/spice-assets/resources/public/documents/591556_6parphoto6.pdf?force_download=true\" target=\"_blank\">will join S&amp;P SmallCap 600</a> prior to the open on&nbsp;Oct. 6.</li>     <li>PARR will replace Forestar Group (NYSE:<a href='https://seekingalpha.com/symbol/FOR' title='Forestar Group Inc.'>FOR</a>), as D.R. Horton is acquiring 75% of FOR, which will drop the company's publicly  available float well below 50% and making it ineligible to remain on the index.</li><li>PLAB will replace Atwood Oceanics (NYSE:<a href='https://seekingalpha.com/symbol/ATW' title='Atwood Oceanics Inc.'>ATW</a>), as Ensco is acquiring the company in a deal expected to be completed soon.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298319\" data-linked=\"Par Pacific, Photronics set to join S&amp;P SmallCap 600\" data-tweet=\"$PARR $PARR $PLAB - Par Pacific, Photronics set to join S&amp;P SmallCap 600 https://seekingalpha.com/news/3298319-par-pacific-photronics-set-to-join-s-and-p-smallcap-600?source=tweet\" data-url=\"https://seekingalpha.com/news/3298319-par-pacific-photronics-set-to-join-s-and-p-smallcap-600\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298315\" data-ts=\"1506634545\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298315-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a> <font color='green'>+11.1%</font>. <a href='https://seekingalpha.com/symbol/SGH' title='SMART Global Holdings'>SGH</a> <font color='green'>+6.6%</font>. <a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a> <font color='green'>+5.9%</font>. <a href='https://seekingalpha.com/symbol/TSN' title='Tyson Foods Inc.'>TSN</a> <font color='green'>+5.4%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+3.6%</font>.</li>     <li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a> <font color='red'>-1.9%</font>. <a href='https://seekingalpha.com/symbol/MBT' title='Mobile TeleSystems'>MBT</a> <font color='red'>-1.6%</font>. <a href='https://seekingalpha.com/symbol/TECK' title='Teck Resources Limited'>TECK</a> <font color='red'>-1.5%</font>. <a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a> <font color='red'>-1.3%</font>. <a href='https://seekingalpha.com/symbol/NXST' title='Nexstar Media Group, Inc.'>NXST</a> <font color='red'>-1.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298315\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$APVO $SGH $ZYNE - After Hours Gainers / Losers https://seekingalpha.com/news/3298315-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3298315-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298311\" data-ts=\"1506632550\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/P\" target=\"_blank\">P</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298311-corvex-trims-pandora-media-stake-to-4_7-from-8_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Corvex trims Pandora Media stake to 4.7% from 8.8%</a></h4><ul>   <li>According to an <a href=\"https://seekingalpha.com/filing/3709910\" target=\"_blank\">SEC filing</a>, Corvex no longer has a stake over 5% in Pandora Media (<a href=\"http://seekingalpha.com/symbol/P\" target=\"_blank\">P</a> <font color='red'>-4.7%</font>).</li>    <li>In a previous 13D filing, Corvex and Managing Partner Keith Meister had reported an 8.8% stake. Today that's trimmed to 4.7%, the amended 13D says.</li>    <li>That amounts to just over 11.4M shares vs. 242.62M shares outstanding.</li>    <li>Yesterday, Meister and Corvex sold 7M shares in a single block trade at $7.85. Shares had closed at $8.07 yesterday and at $7.69 today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298311\" data-linked=\"Corvex trims Pandora Media stake to 4.7% from 8.8%\" data-tweet=\"$P - Corvex trims Pandora Media stake to 4.7% from 8.8% https://seekingalpha.com/news/3298311-corvex-trims-pandora-media-stake-to-4_7-from-8_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3298311-corvex-trims-pandora-media-stake-to-4_7-from-8_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>72&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298291\" data-ts=\"1506630602\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATEN\" target=\"_blank\">ATEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298291-a10-sharesplus-20-after-raising-q3-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">A10 shares +20% after raising Q3 guidance</a></h4><ul><li>        A10 Networks (NYSE:<a href='https://seekingalpha.com/symbol/ATEN' title='A10 Networks, Inc.'>ATEN</a>) shares&nbsp;<font color='green'>soar 20.3%&nbsp;</font>aftermarket after the company <a href=\"https://seekingalpha.com/pr/16954667-a10-networks-expects-third-quarter-2017-revenue-exceed-prior-outlook\" target=\"_blank\">raise</a>d&nbsp;its Q3 guidance.</li><li>               Q3 outlook now puts revenue from $59M to $60M, up from $53M to $579M, compared to the $55.61M consensus. The company expects to report a non-GAAP profit.&nbsp;</li><li>               A10 also announces the departure of EVP of worldwide sales Ray Smets effective in Q4. CFO Tom Constantino will step into the role on an interim basis.&nbsp;&nbsp; &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298291\" data-linked=\"A10 shares +20% after raising Q3 guidance\" data-tweet=\"$ATEN - A10 shares +20% after raising Q3 guidance https://seekingalpha.com/news/3298291-a10-sharesplus-20-after-raising-q3-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3298291-a10-sharesplus-20-after-raising-q3-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298290\" data-ts=\"1506630505\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSN\" target=\"_blank\">TSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298290-tyson-foods-up-nearly-4-after-guidance-boost-savings-targets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tyson Foods up nearly 4% after guidance boost, savings targets</a></h4><ul><li>Adjusted EPS guidance for fiscal 2017 (ending Saturday) is boosted to $5.20-$5.30 from $4.95-$5.05.</li><li>Fiscal 2018 EPS is seen at $5.70-$5.85.</li><li>Between the integration of the recent AdvancePierre acquisition and other initiatives, the company expects cumulative net savings of $200M, $400M, and $600M over fiscals 2018, 2019, and 2020, respectively.</li><li><a href='https://seekingalpha.com/symbol/TSN' title='Tyson Foods Inc.'>TSN</a>&nbsp;<font color='green'>+3.9%</font>&nbsp;after hours</li><li>Source: <a href=\"https://seekingalpha.com/pr/16954679-tyson-foods-boosts-fy2017-eps-guidance-strong-beef-segment-performance\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3298290\" data-linked=\"Tyson Foods up nearly 4% after guidance boost, savings targets\" data-tweet=\"$TSN - Tyson Foods up nearly 4% after guidance boost, savings targets https://seekingalpha.com/news/3298290-tyson-foods-up-nearly-4-after-guidance-boost-savings-targets?source=tweet\" data-url=\"https://seekingalpha.com/news/3298290-tyson-foods-up-nearly-4-after-guidance-boost-savings-targets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298284\" data-ts=\"1506629977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAMP\" target=\"_blank\">CAMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298284-calamp-beats-profit-revenue-expectations-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CalAmp beats profit, revenue expectations with Q2</a></h4><ul>   <li>CalAmp (<a href=\"http://seekingalpha.com/symbol/CAMP\" target=\"_blank\">CAMP</a> <font color='green'>+2.2%</font>) posted beats on top and bottom lines with <a href=\"https://seekingalpha.com/news/3298276-calamp-beats-0_01-beats-revenue\" target=\"_blank\">Q2 earnings</a> that showed progress in its newer areas of focus, including connected vehicles and industrial Internet of Things.</li>    <li>Revenues grew in continuing businesses (up 7.1% combined), but declined fractionally overall without $6.67M in year-ago earnings from its satellite business that ceased operations Aug. 31, 2016.</li>    <li>Gross margin dipped slightly, to 41% from 41.6%.</li>    <li>Revenue breakout: Telematics Systems, $74.1M (up 7.6%); Software and Subscription Services, $15.7M (up 4.95%).</li>    <li>At quarter's end, cash and marketable securities were $130.6M, and total debt outstanding was $150.5M.</li>    <li>For Q3 it's guiding to revenues of $89M-$94M (vs. consensus for $90.8M) and adjusted EPS of $0.27-$0.33 (in line with consensus for $0.30). It's also forecasting EBITDA of $12M-$14.5M vs. expectations for $13.3M.</li>    <li><a href=\"http://investor.calamp.com/phoenix.zhtml?c=80120&amp;p=irol-EventDetails&amp;EventId=5263363\" target=\"_blank\">Conference call</a> to come at 4:30 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16954654-calamp-reports-second-quarter-fiscal-2018-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3298284\" data-linked=\"CalAmp beats profit, revenue expectations with Q2\" data-tweet=\"$CAMP - CalAmp beats profit, revenue expectations with Q2 https://seekingalpha.com/news/3298284-calamp-beats-profit-revenue-expectations-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3298284-calamp-beats-profit-revenue-expectations-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298271\" data-ts=\"1506628807\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAT\" target=\"_blank\">AMAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298271-applied-materials-up-after-jpmorgan-lists-multiple-tailwinds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Materials up after JPMorgan lists multiple tailwinds</a></h4><ul><li>        Applied Materials (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a>) shares are&nbsp;<font color='green'>up 3.44%</font>&nbsp;after a <a href=\"https://www.cnbc.com/2017/09/28/buy-applied-materials-because-of-the-chip-making-boom-jpmorgan.html\" target=\"_blank\">JPMorgan analyst</a> says the company is well positioned to ride the major tech trends coming in the next three years. &nbsp;</li><li>        Analyst Harlan Sur cites the potential for low percentage point gains in silicon business, a broadening portfolio of products with increasing penetration, increased wafer capacity intensity, and display market exposure as the multiple tailwinds for Applied Materials.</li><li>               Sur reiterates an Overweight rating on the company.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297975-applied-materials-provides-three-year-guidance-shares-7_5-percent\" target=\"_blank\">Applied Materials provides three-year guidance; shares up 7.5%</a> (Sept. 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298137-evercore-isi-raises-applied-materials-price-target-analyst-day\" target=\"_blank\">Evercore ISI raises Applied Materials price target after Analyst Day</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298271\" data-linked=\"Applied Materials up after JPMorgan lists multiple tailwinds\" data-tweet=\"$AMAT - Applied Materials up after JPMorgan lists multiple tailwinds https://seekingalpha.com/news/3298271-applied-materials-up-after-jpmorgan-lists-multiple-tailwinds?source=tweet\" data-url=\"https://seekingalpha.com/news/3298271-applied-materials-up-after-jpmorgan-lists-multiple-tailwinds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298270\" data-ts=\"1506628769\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FINL\" target=\"_blank\">FINL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298270-finish-line-said-to-be-exploring-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finish Line said to be exploring sale</a></h4><ul><li>Finish Line (<a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a> <font color='green'>+3.9%</font>) is in talks to <a href=\"http://nypost.com/2017/09/28/finish-line-in-talks-to-sell-itself-to-a-british-retailer/\" target=\"_blank\">sell </a>itself, according to New York Post.</li><li>Sources indicate that the interested party is a British retailer.</li><li>Sports Direct International might top the list of (<a href='https://seekingalpha.com/symbol/SDIPF' title='Sports Direct International Plc.'>OTCPK:SDIPF</a>) of potential buyers due to its 8% stake in Finish Line.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298270\" data-linked=\"Finish Line said to be exploring sale\" data-tweet=\"$FINL $FINL $SDIPF - Finish Line said to be exploring sale https://seekingalpha.com/news/3298270-finish-line-said-to-be-exploring-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3298270-finish-line-said-to-be-exploring-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298268\" data-ts=\"1506628511\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTCT\" target=\"_blank\">PTCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298268-fda-ad-com-says-data-on-ptcs-translarna-inclusive-needed-to-prove-efficacy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA Ad Com says data on PTC&#39;s Translarna inclusive, more needed to prove efficacy</a></h4><ul><li>The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted that the data supporting PTC Therapeutics' (<a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a>) marketing application seeking approval for Translarna (ataluren) for the treatment of dystrophinopathy due to a nonsense mutation in the dystrophin gene (includes Duchenne muscular dystrophy patients) was inconclusive (10 of 11 votes). There was one vote in favor that the data demonstrated effectiveness.</li><li>The committee's position is that more data are needed to prove that the drug works.</li><li>Sarepta Therapeutics (<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='green'>+1%</font>), maker of DMD drug EXONDYS 51, has moved up on the news.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297574-investors-shaken-ptcs-briefing-docs-ahead-ad-com-dmd-candidate-translarna-shares-14-percent\" target=\"_blank\">Investors shaken by PTC's briefing docs ahead of Ad Com for DMD candidate Translarna; shares down 14% premarket</a> (Sept. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298268\" data-linked=\"FDA Ad Com says data on PTC&#39;s Translarna inclusive, more needed to prove efficacy\" data-tweet=\"$PTCT $PTCT $SRPT - FDA Ad Com says data on PTC&#39;s Translarna inclusive, more needed to prove efficacy https://seekingalpha.com/news/3298268-fda-ad-com-says-data-on-ptcs-translarna-inclusive-needed-to-prove-efficacy?source=tweet\" data-url=\"https://seekingalpha.com/news/3298268-fda-ad-com-says-data-on-ptcs-translarna-inclusive-needed-to-prove-efficacy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298269\" data-ts=\"1506628380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NDRO-OLD\" target=\"_blank\">NDRO-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298269-enduro-trust-downgraded-stifel-special-distribution-priced-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enduro Trust downgraded at Stifel, as special distribution priced in</a></h4><ul>     <li>Enduro Royalty Trust (<a href='https://seekingalpha.com/symbol/NDRO-OLD' title='Enduro Royalty Trust'>NDRO-OLD</a> <font color='green'>+2.4%</font>) is <a href=\"https://www.streetinsider.com/Analyst+Comments/Stifel+Downgrades+Enduro+Royalty+Trust+%28NDRO%29+to+Hold/13335971.html\" target=\"_blank\">downgraded</a> to Hold from Buy with a $4 price target at Stifel, which reminds investors that the trust was trading near $3 prior to the  announcement of the targeted asset sale, resulting in a significant special distribution to unitholders.</li>     <li>While oil prices have modestly improved since early June, Sitfel sees the current price effectively pricing in the one-time <a href=\"https://seekingalpha.com/news/3297447-enduro-royalty-trust-declares-1_150005-dividend\" target=\"_blank\">$1.15/unit distribution</a> set for Oct. 20.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298269\" data-linked=\"Enduro Trust downgraded at Stifel, as special distribution priced in\" data-tweet=\"$NDRO-OLD - Enduro Trust downgraded at Stifel, as special distribution priced in https://seekingalpha.com/news/3298269-enduro-trust-downgraded-stifel-special-distribution-priced-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3298269-enduro-trust-downgraded-stifel-special-distribution-priced-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298267\" data-ts=\"1506627751\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOSBF\" target=\"_blank\">TOSBF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298267-toshiba-memory-ipo-coming-in-2020\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toshiba Memory IPO coming in 2020?</a></h4><ul><li>        Bain Capital hopes to take Toshiba&rsquo;s (<a href='https://seekingalpha.com/symbol/TOSBF' title='Toshiba Corp.'>OTCPK:TOSBF</a>, <a href='https://seekingalpha.com/symbol/TOSYY' title='Toshiba Corp. ADR'>OTCPK:TOSYY</a>) memory unit public within three years, according to <a href=\"https://www.bloomberg.com/news/articles/2017-09-28/bain-is-said-to-aim-for-toshiba-chip-unit-ipo-as-soon-as-2020\" target=\"_blank\">Bloomberg</a> sources. &nbsp;</li><li>        Toshiba and a Bain-led consortium signed a $18B deal this morning to offload the chip unit and save Toshiba from a March delisting from the Tokyo exchange.</li><li>               The memory IPO timing will depend on finances and market conditions so the situation is fluid. Bain plans to institute an employee stock option program at the unit so workers could benefit.&nbsp;</li><li>               Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) still plans to fight the chip unit&rsquo;s sale, arguing contractual consent rights due to its acquisition last year of Toshiba partner SanDisk, and those legal matters might not finish until 2019.&nbsp;</li><li>               If courts don&rsquo;t issue an injunction blocking the entire chip unit&rsquo;s transfer, Toshiba will sell everything but the three joint ventures with Western Digital and the bid price will adjust accordingly.&nbsp;</li><li>               Western Digital shares are&nbsp;<font color='red'>down 2.19%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298057-toshiba-signs-18b-deal-sell-chip-unit\" target=\"_blank\">Toshiba signs $18B deal to sell chip unit</a> (Sept. 28)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298094-seagate-contributes-1_25b-toshiba-deal-sk-hynix-will-act-limited-partner\" target=\"_blank\">Seagate contributes $1.25B to Toshiba deal; SK Hynix will act as limited partner</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298267\" data-linked=\"Toshiba Memory IPO coming in 2020?\" data-tweet=\"$TOSBF $TOSBF $TOSYY - Toshiba Memory IPO coming in 2020? https://seekingalpha.com/news/3298267-toshiba-memory-ipo-coming-in-2020?source=tweet\" data-url=\"https://seekingalpha.com/news/3298267-toshiba-memory-ipo-coming-in-2020\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298266\" data-ts=\"1506627250\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298266-fda-oks-lillys-breast-cancer-drug-abemaciclib-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Lilly&#39;s breast cancer drug abemaciclib; shares up 1%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16954525-fda-approves-new-treatment-certain-advanced-metastatic-breast-cancers\" target=\"_blank\">approves</a> Eli Lilly's (<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color='green'>+0.8%</font>) Verzenio (abemaciclib), in combination with AstraZeneca's Faslodex (fulvestrant), for the treatment of adult patients with hormone receptor &#40;HR&#41;-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer that has progressed after endocrine therapy. The approval also includes Verzenio as monotherapy in HR+/HER2- breast cancer patients who have been previously treated with endocrine therapy and chemo after metastasis.</li><li>The approval was granted early even considering its Priority Review status. A decision was actually expected in Q1 2018.</li><li>Breakthrough Therapy-tagged abemaciclib is a cell cycle inhibitor that is designed to block the growth of cancer cells by inhibiting the enzymes&nbsp;<a href=\"https://en.wikipedia.org/wiki/Cyclin-dependent_kinase_4\" target=\"_blank\">CDK4&nbsp;</a>and&nbsp;<a href=\"https://en.wikipedia.org/wiki/Cyclin-dependent_kinase_6\" target=\"_blank\">CDK6</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277640-fda-grants-accelerated-review-lillys-breast-cancer-candidate-abemaciclib\" target=\"_blank\">FDA grants accelerated review for Lilly's breast cancer candidate abemaciclib</a> (July 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298266\" data-linked=\"FDA OKs Lilly&#39;s breast cancer drug abemaciclib; shares up 1%\" data-tweet=\"$LLY - FDA OKs Lilly&#39;s breast cancer drug abemaciclib; shares up 1% https://seekingalpha.com/news/3298266-fda-oks-lillys-breast-cancer-drug-abemaciclib-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3298266-fda-oks-lillys-breast-cancer-drug-abemaciclib-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298261\" data-ts=\"1506626240\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298261-gilead-sells-off-whistleblower-suit-revived-appeals-court-shares-down-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gilead sells off, whistleblower suit revived by appeals court; shares down 5%</a></h4><ul><li>Gilead Sciences (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='red'>-4.8%</font>) is down on modestly higher volume. The downward action is not too surprising considering the stock's ~35% runup from mid-June.</li><li>After the close yesterday, the company announced the retirement of COO Kevin Young, not unexpected he came out of retirement to take the job.</li><li>Also after the close yesterday, Forbes <a href=\"https://www.forbes.com/sites/erikakelton/2017/09/26/revival-of-gilead-whistleblowers-lawsuit-should-stoke-fear-in-big-pharma/#263fba6e2837\" target=\"_blank\">reported </a>that the Ninth Circuit Court of Appeals has revived a whistleblower suit that was dismissed at the district level in 2015. The suit, <em>U.S. ex. rel. Campie v. Gilead Sciences Inc.</em>, was brought by two former Gilead employees who claimed the company violated the False Claims Act by misleading the FDA about the source and quality of active ingredients in HIV drugs Emtriva, Truvada and Atripla. Specifically, the company informed the agency that it sourced the material from approved sites in Canada, Germany, South Korea and the U.S. when, in fact, it sourced it from an unapproved manufacturer in China.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298011-gilead-operating-chief-retire-q1-2018\" target=\"_blank\">Gilead operating chief to retire in Q1 2018</a> (Sept. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298261\" data-linked=\"Gilead sells off, whistleblower suit revived by appeals court; shares down 5%\" data-tweet=\"$GILD - Gilead sells off, whistleblower suit revived by appeals court; shares down 5% https://seekingalpha.com/news/3298261-gilead-sells-off-whistleblower-suit-revived-appeals-court-shares-down-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3298261-gilead-sells-off-whistleblower-suit-revived-appeals-court-shares-down-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>87&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298258\" data-ts=\"1506625296\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298258-valeant-filing-misunderstood-wells-fargo-shares-cut-losses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeant filing misunderstood - Wells Fargo; shares cut losses</a></h4><ul><li>This morning's filing with Canadian regulators was misunderstood by investors, says Wells Fargo - it's not for a potential equity raise.</li><li>VRX is&nbsp;<font color='red'>4.8% lower</font>&nbsp;on the session, but was down about 7% prior to the Wells headlines coming across Bloomberg.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298183-valeant-slumps-disclosure-filing-financing-transaction-shares-5-percent\" target=\"_blank\">Valeant slumps on disclosure of filing for financing transaction; shares down 5%</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298258\" data-linked=\"Valeant filing misunderstood - Wells Fargo; shares cut losses\" data-tweet=\"$BHC - Valeant filing misunderstood - Wells Fargo; shares cut losses https://seekingalpha.com/news/3298258-valeant-filing-misunderstood-wells-fargo-shares-cut-losses?source=tweet\" data-url=\"https://seekingalpha.com/news/3298258-valeant-filing-misunderstood-wells-fargo-shares-cut-losses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>80&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298254\" data-ts=\"1506624924\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298254-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EXA' title='Exa Corporation'>EXA</a> <font color='green'>+43%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+18%</font>. WPCS <font color='green'>+17%</font>. BBRY <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/AEHR' title='Aehr Test Systems'>AEHR</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/CMTL' title='Comtech Telecommunications Corp.'>CMTL</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/NTWK' title='NetSol Technologies Inc.'>NTWK</a> <font color='red'>-14%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298254\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$EXA $HMNY $DCAR - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3298254-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3298254-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298249\" data-ts=\"1506622784\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LXU\" target=\"_blank\">LXU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298249-lsb-industriesminus-12-fire-takes-oklahoma-plant-out-of-service\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LSB Industries -12% as fire takes Oklahoma plant out of service</a></h4><ul>     <li>LSB&nbsp;Industries (<a href='https://seekingalpha.com/symbol/LXU' title='LSB Industries, Inc.'>LXU</a> <font color='red'>-12.4%</font>) sinks following news that its Pryor, Okla., ammonia plant was <a href=\"https://seekingalpha.com/pr/16953648-lsb-industries-inc-provides-operational-update-pryor-oklahoma-facility\" target=\"_blank\">taken out of service</a> on Sept. 23 after a fire damaged some of the plant&rsquo;s electrical controls, wiring and piping.</li>     <li>LSB expects the repairs to be completed and ammonia production to resume by the end of October.</li><li>LSB expects a $1.5M-$2M impact to Q3 EBITDA and $2.5M-$2.75M to Q4 resulting from the repair  expenses, the excess cost of purchasing UAN versus producing it and the reduced absorption of fixed costs.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298249\" data-linked=\"LSB Industries -12% as fire takes Oklahoma plant out of service\" data-tweet=\"$LXU - LSB Industries -12% as fire takes Oklahoma plant out of service https://seekingalpha.com/news/3298249-lsb-industriesminus-12-fire-takes-oklahoma-plant-out-of-service?source=tweet\" data-url=\"https://seekingalpha.com/news/3298249-lsb-industriesminus-12-fire-takes-oklahoma-plant-out-of-service\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298247\" data-ts=\"1506622364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTNX\" target=\"_blank\">NTNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298247-information-nutanix-ceo-turned-down-acquisition-offers-from-cisco-hp\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Information: Nutanix CEO turned down acquisition offers from Cisco, HP</a></h4><ul><li>        Nutanix (NASDAQ:<a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a>) CEO Dheeraj Pandey tells <a href=\"https://www.theinformation.com/articles/nutanix-takes-on-microsoft-vmware-in-cloud?jwt=eyJhbGciOiJIUzI1NiJ9.eyJzdWIiOiJiYmV0ekBzZWVraW5nYWxwaGEuY29tIiwiZXhwIjoxNTM4MTc5MzY3LCJuIjoiR3Vlc3QiLCJzY29wZSI6WyJzaGFyZSJdfQ.9aks07ld8Wl_rHcPXp9y-Kik5oT00NC9molLtsilFzY&amp;unlock=38a958708015b67f\" target=\"_blank\">The Information</a> that turned down acquisition offers from Hewlett-Packard and Cisco Systems before his company&rsquo;s IPO last year.</li><li>        Pandey on turning down the offers: &ldquo;I think the fact that we had happy customers, a great Net Promoter score, and good growth was telling us that the best was ahead. We thought, 'Why not try to build a larger company?&rsquo;&rdquo;</li><li>        In its first full-year report, Nutanix reported $767M in revenue, up 72% on the year, but net losses increased 171% to $458M.</li><li>               Nutanix shares are&nbsp;<font color='red'>down 4.13%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298247\" data-linked=\"The Information: Nutanix CEO turned down acquisition offers from Cisco, HP\" data-tweet=\"$NTNX - The Information: Nutanix CEO turned down acquisition offers from Cisco, HP https://seekingalpha.com/news/3298247-information-nutanix-ceo-turned-down-acquisition-offers-from-cisco-hp?source=tweet\" data-url=\"https://seekingalpha.com/news/3298247-information-nutanix-ceo-turned-down-acquisition-offers-from-cisco-hp\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298244\" data-ts=\"1506621696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298244-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/OMN' title='OMNOVA Solutions Inc.'>OMN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/HBM' title='Hudbay Minerals Inc Ordinary Sh'>HBM</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/LXU' title='LSB Industries, Inc.'>LXU</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PES' title='Pioneer Energy Services'>PES</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/AAU' title='Almaden Minerals Ltd'>AAU</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FTK' title='Flotek Industries, Inc.'>FTK</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298244\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$ROSE $OMN $WMLP-OLD - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3298244-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3298244-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298243\" data-ts=\"1506621687\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALR\" target=\"_blank\">ALR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298243-alere-to-divest-two-product-lines-to-get-ftc-signoff-on-abbott-merger-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alere to divest two product lines to get FTC signoff on Abbott merger; shares up 4%</a></h4><ul><li>Alere (<a href='https://seekingalpha.com/symbol/ALR' title='Alere Inc.'>ALR</a> <font color='green'>+3.6%</font>) is up more than double normal volume as it moves closer to the finish line with Abbott. It appears that the Federal Trade Commission &#40;FTC&#41; will <a href=\"https://www.ftc.gov/news-events/press-releases/2017/09/ftc-requires-abbott-laboratories-divest-two-types-point-care\" target=\"_blank\">OK the transaction</a> if the company divests two product lines: its blood gas testing system (Siemens Aktiengelsellschaft is the buyer) and it cardiac marker testing system (Quidel is the buyer). The divestments include two Canadian facilities to Siemens and one to Quidel.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3288978-abbott-extends-offer-buy-alere-convertible-preferred-end-month\" target=\"_blank\">Abbott extends offer to buy Alere convertible preferred to the end of month</a> (Aug. 14)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3278871-quidel-announces-definitive-agreement-acquire-alere-triage-assets\" target=\"_blank\">Quidel announces definitive agreement to acquire Alere Triage Assets</a> (July 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298243\" data-linked=\"Alere to divest two product lines to get FTC signoff on Abbott merger; shares up 4%\" data-tweet=\"$ALR - Alere to divest two product lines to get FTC signoff on Abbott merger; shares up 4% https://seekingalpha.com/news/3298243-alere-to-divest-two-product-lines-to-get-ftc-signoff-on-abbott-merger-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3298243-alere-to-divest-two-product-lines-to-get-ftc-signoff-on-abbott-merger-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298239\" data-ts=\"1506620048\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIIQ\" target=\"_blank\">HIIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298239-health-insurance-innovations-under-pressure-again-on-alleged-ties-to-dubious-brokers-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Health Insurance Innovations under pressure again on alleged ties to dubious brokers; shares down 29%</a></h4><ul><li>Investors in Health Insurance Innovations (<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='red'>-28.8%</font>)&nbsp;are running for the exits again. The negative catalyst this time is a <a href=\"https://seekingalpha.com/instablog/38059736-the-friendly-bear/5048086-hiiq-100-percent-downside-problematic-broker-relationships\" target=\"_blank\">blog post</a> by SA Contributor The Friendly Bear. Key points:</li><li>Up to 86% of sales could linked to brokers with dubious backgrounds, a multi-state investigation may be in the offing.</li><li>Top third-party broker is controlled by Steven Dorfman who has a criminal background and history of selling insurance without a license. Two months ago, his company was implicated in an insurance fraud scheme in Nebraska.</li><li>Company has allegedly advanced commissions to certain brokers to finance their operations, what FB calls \"glorified boiler room financing.\"</li><li>Shares tumbled several weeks ago after SA Contributor Richard Pearson published a bearish article.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294627-health-insurance-innovations-pressure-bearish-report-sa-contributor-pearson-shares-14-percent\" target=\"_blank\">Health Insurance Innovations under pressure on bearish report from SA Contributor Pearson; shares down 14%</a> (Sept. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298239\" data-linked=\"Health Insurance Innovations under pressure again on alleged ties to dubious brokers; shares down 29%\" data-tweet=\"$HIIQ - Health Insurance Innovations under pressure again on alleged ties to dubious brokers; shares down 29% https://seekingalpha.com/news/3298239-health-insurance-innovations-under-pressure-again-on-alleged-ties-to-dubious-brokers-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3298239-health-insurance-innovations-under-pressure-again-on-alleged-ties-to-dubious-brokers-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298237\" data-ts=\"1506619618\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFL\" target=\"_blank\">AFL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298237-aflac-down-nearly-2-after-meeting-analysts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aflac down nearly 2% after meeting with analysts</a></h4><ul><li>Details are scare for now, but Bloomberg reports KBW's Ryan Krueger saying the company's capital deployment outlook of $5.75B-$6.5B is shy of his estimate of $6.9B.</li><li><a href='https://seekingalpha.com/symbol/AFL' title='Aflac Incorporated'>AFL</a> adding to losses in the last few minutes, now&nbsp;<font color='red'>down 1.9%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297525-aflac-slips-half-percent-citi-cuts-sell\" target=\"_blank\">Aflac slips half-a-percent as Citi cuts to Sell</a> (Sept. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298237\" data-linked=\"Aflac down nearly 2% after meeting with analysts\" data-tweet=\"$AFL - Aflac down nearly 2% after meeting with analysts https://seekingalpha.com/news/3298237-aflac-down-nearly-2-after-meeting-analysts?source=tweet\" data-url=\"https://seekingalpha.com/news/3298237-aflac-down-nearly-2-after-meeting-analysts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298236\" data-ts=\"1506619521\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAL\" target=\"_blank\">AAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298236-american-airlines-higher-after-positive-tone-from-investor-day-event\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Airlines higher after positive tone from investor day event</a></h4><ul>     <li>American Airlines Group (NASDAQ:<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group'>AAL</a>) is&nbsp;<font color='green'>up 1.28%&nbsp;</font>after a rosy presentation by management at the company's investor day event.</li><li>While the company's unit revenue forecast for Q3 was lowered to +0.5% growth due partially from the impact of hurricanes, the long term outlook from execs was very favorable.</li><li>The size of the American's network is seen as an advantage as ancillary revenue continues to grow and gains in efficiency factor in.</li><li>\"I don't think we're ever going to lose money again,\" stated American CEO Doug Parker</li>          <li><a href=\"http://phx.corporate-ir.net/phoenix.zhtml?c=117098&amp;p=irol-IRHome&amp;anchorLocation=DirectURL&amp;title=investorrelations\" target=\"_blank\">American Airlines investor day webcast</a></li>      </ul><div class=\"tiny-share-widget\" data-id=\"3298236\" data-linked=\"American Airlines higher after positive tone from investor day event\" data-tweet=\"$AAL - American Airlines higher after positive tone from investor day event https://seekingalpha.com/news/3298236-american-airlines-higher-after-positive-tone-from-investor-day-event?source=tweet\" data-url=\"https://seekingalpha.com/news/3298236-american-airlines-higher-after-positive-tone-from-investor-day-event\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298235\" data-ts=\"1506619499\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWER\" target=\"_blank\">TWER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298235-towerstream-to-reverse-split-1-forminus-75-tomorrow\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Towerstream to reverse split 1-for-75 before tomorrow</a></h4><ul>   <li>Fixed-wireless firm Towerstream (NASDAQ:<a href='https://seekingalpha.com/symbol/TWER-OLD' title='Towerstream Corporation'>TWER</a>), whose stock fell below the $1 mark last November and is trading at $0.08 today, is <font color='red'>off 4.5%</font> after news that it will <a href=\"https://seekingalpha.com/pr/16953963-towerstream-announces-reverse-split-common-stock\" target=\"_blank\">reverse split</a> its stock 1-for-75.</li>    <li>Shares will trade on an adjusted basis starting tomorrow (under a temporary ticker of \"TWERD\" for 20 trading days, before reverting to <a href='https://seekingalpha.com/symbol/TWER-OLD' title='Towerstream Corporation'>TWER</a>).</li>    <li>Fractional shares will be rounded up to the nearest whole share; those with paper certificates may need to send them to the company's transfer agent.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298235\" data-linked=\"Towerstream to reverse split 1-for-75 before tomorrow\" data-tweet=\"$TWER $TWER-OLD - Towerstream to reverse split 1-for-75 before tomorrow https://seekingalpha.com/news/3298235-towerstream-to-reverse-split-1-forminus-75-tomorrow?source=tweet\" data-url=\"https://seekingalpha.com/news/3298235-towerstream-to-reverse-split-1-forminus-75-tomorrow\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298233\" data-ts=\"1506618377\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298233-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/BYBK' title='Bay Bancorp, Inc.'>BYBK</a> <font color='green'>+41%</font>. <a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FOR' title='Forestar Group Inc.'>FOR</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/WHLR' title='Wheeler Real Estate Investment Trust'>WHLR</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298233\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$BYBK $FANH $FOR - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3298233-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3298233-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298227\" data-ts=\"1506617162\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298227-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AMMA-OLD' title='Alliance MMA'>AMMA-OLD</a> <font color='green'>+123%</font>. <a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a> <font color='green'>+57%</font>. <a href='https://seekingalpha.com/symbol/EXA' title='Exa Corporation'>EXA</a> <font color='green'>+43%</font>. <a href='https://seekingalpha.com/symbol/BYBK' title='Bay Bancorp, Inc.'>BYBK</a> <font color='green'>+41%</font>. <a href='https://seekingalpha.com/symbol/OMNT' title='Ominto, Inc.'>OTCPK:OMNT</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/MDGL' title='Madrigal Pharmaceuticals, Inc.'>MDGL</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/AQMS' title='Aqua Metals'>AQMS</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='green'>+18%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a> <font color='red'>-34%</font>. <a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='red'>-26%</font>. ITUS <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/CMTL' title='Comtech Telecommunications Corp.'>CMTL</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ANGO' title='AngioDynamics, Inc.'>ANGO</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/NTWK' title='NetSol Technologies Inc.'>NTWK</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ROSG-OLD' title='Rosetta Genomics Ltd.'>ROSG-OLD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='red'>-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298227\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$AMMA-OLD $ZYNE $EXA - Midday Gainers / Losers https://seekingalpha.com/news/3298227-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3298227-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298225\" data-ts=\"1506616515\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBL\" target=\"_blank\">NBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298225-israels-top-court-leaves-door-open-for-lawsuit-against-tamar-partners\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Israel&#39;s top court leaves door open for lawsuit against Tamar partners</a></h4><ul>     <li>Israel's Supreme Court says it <a href=\"https://www.bloomberg.com/news/articles/2017-09-28/israel-gas-stocks-tumble-after-high-court-opens-door-for-lawsuit\" target=\"_blank\">will not dismiss a class action lawsuit</a> against the partners in the Tamar natural gas field that claims the companies have charged unfair and monopolistic prices.</li>     <li>Noble Energy (<a href='https://seekingalpha.com/symbol/NBL' title='Noble Energy, Inc.'>NBL</a> <font color='red'>-1.9%</font>) and the Israeli companies belonging to the Tamar consortium - including Delek Drilling (<a href='https://seekingalpha.com/symbol/DKDRF' title='Delek Drilling'>OTC:DKDRF</a>), Isramco Negev (NASDAQ:<a href='https://seekingalpha.com/symbol/ISRL' title='Isramco, Inc.'>ISRL</a>) and Tamar Petroleum - are sharply lower after the decision.</li>     <li>The Tamar partners describe the court ruling as purely procedural and predict the suit eventually will be thrown out.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298225\" data-linked=\"Israel&#39;s top court leaves door open for lawsuit against Tamar partners\" data-tweet=\"$NBL $NBL $DKDRF - Israel&#39;s top court leaves door open for lawsuit against Tamar partners https://seekingalpha.com/news/3298225-israels-top-court-leaves-door-open-for-lawsuit-against-tamar-partners?source=tweet\" data-url=\"https://seekingalpha.com/news/3298225-israels-top-court-leaves-door-open-for-lawsuit-against-tamar-partners\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298223\" data-ts=\"1506616113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CI\" target=\"_blank\">CI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298223-health-insurers-and-hmos-up-on-potential-deal-to-stabilize-aca\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Health insurers and HMOs up on potential deal to stabilize ACA</a></h4><ul><li>Health Insurance and HMO firms perk up on reports that a deal is in the works to stabilize the exchange-offered individual health insurance market (Obamacare). Companies have been bailing out of many local exchanges because they are losing money and insurance buyers have been faced with sharply higher premiums, forcing many to cancel their coverage.</li><li>(<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a> <font color='green'>+1.4%</font>)(<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a> <font color='green'>+1.5%</font>)(<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a> <font color='green'>+0.5%</font>)(<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a> <font color='green'>+2%</font>)(<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a> <font color='green'>+1.4%</font>)(<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a> <font color='green'>+1.5%</font>)</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3298223\" data-linked=\"Health insurers and HMOs up on potential deal to stabilize ACA\" data-tweet=\"$CI $CI $AET - Health insurers and HMOs up on potential deal to stabilize ACA https://seekingalpha.com/news/3298223-health-insurers-and-hmos-up-on-potential-deal-to-stabilize-aca?source=tweet\" data-url=\"https://seekingalpha.com/news/3298223-health-insurers-and-hmos-up-on-potential-deal-to-stabilize-aca\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298217\" data-ts=\"1506614450\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298217-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/FBR' title='Fibria Celulose S.A.'>FBR</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/BSET' title='Bassett Furniture Industries, Incorporated'>BSET</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/ROX' title='Castle Brands Inc'>ROX</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corp'>VUZI</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298217\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$REV $WPRT $FBR - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3298217-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3298217-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298213\" data-ts=\"1506613841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/K\" target=\"_blank\">K</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298213-susquehanna-on-kelloggs-ceo-pick\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Susquehanna on Kellogg&#39;s CEO pick</a></h4><ul> <li>Susquehanna analyst Pablo Zuanic chimes in on the new CEO picked by Kellogg (<a href='https://seekingalpha.com/symbol/K' title='Kellogg Company'>K</a> <font color='red'>-0.5%</font>)&nbsp;in what's the first move outside the company for the top spot in years.</li> <li>\"We do not expect radical changes at K (a mega merger or company sale), but would think the Kapoor model may be the blue print &ndash; i.e., gradually transform the portfolio through acquisitions,\" he writes.</li> <li>The \"Kapoor model\" refers to the chief at Reckitt Benckiser who transformed the company by diversifying away from household/personal care into consumer health care.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298139-steven-cahillane-appointed-new-ceo-kellogg-john-bryant-retires\" target=\"_blank\">Steven A. Cahillane appointed as new CEO of Kellogg as John A. Bryant retires</a> (Sept. 28)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298213\" data-linked=\"Susquehanna on Kellogg&#39;s CEO pick\" data-tweet=\"$K - Susquehanna on Kellogg&#39;s CEO pick https://seekingalpha.com/news/3298213-susquehanna-on-kelloggs-ceo-pick?source=tweet\" data-url=\"https://seekingalpha.com/news/3298213-susquehanna-on-kelloggs-ceo-pick\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298212\" data-ts=\"1506613591\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HHS\" target=\"_blank\">HHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298212-harte-hanksplus-6_5-revenue-declines-slow\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harte Hanks +6.5% as revenue declines slow</a></h4><ul>   <li>Harte Hanks (NYSE:<a href='https://seekingalpha.com/symbol/HHS' title='Harte Hanks Inc.'>HHS</a>) is <font color='green'>up 6.5%</font> and hitting its highest point since July, following a <a href=\"https://seekingalpha.com/news/3298086-harte-hanks-misses-0_01-beats-revenue\" target=\"_blank\">Q2 earnings report</a> where revenues slowed less than expected and the company improved operating losses year-over-year.</li>    <li>Revenues dropped 2.7%, continuing a trend of slowing declines, and net loss from continuing operations improved by $4.3M, to a loss of $2.7M.</li>    <li>Revenue mix: Auto and consumer brands, 25.2%; Financial and Insurance Services, 15.5%; Healthcare and Pharmaceuticals, 5.4%; B2B, 21.6%; Retail, 24.1%; Transportation, 8.2%.</li>    <li>&ldquo;During the quarter our cash flows included payment of $34M in taxes related to the Trillium sale, $1.3M for capital expenditures, and $2M for a lawsuit loss accrued in 2016,\" says CFO Robert Munden, adding that the company expects net cash will improve in the second half.</li>    <li><a href=\"https://seekingalpha.com/pr/16953569-harte-hanks-reports-second-quarter-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3298212\" data-linked=\"Harte Hanks +6.5% as revenue declines slow\" data-tweet=\"$HHS - Harte Hanks +6.5% as revenue declines slow https://seekingalpha.com/news/3298212-harte-hanksplus-6_5-revenue-declines-slow?source=tweet\" data-url=\"https://seekingalpha.com/news/3298212-harte-hanksplus-6_5-revenue-declines-slow\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298204\" data-ts=\"1506612093\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEMI\" target=\"_blank\">CEMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298204-fda-oks-emergency-use-of-chembios-rapid-zika-test-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs emergency use of Chembio&#39;s rapid Zika test; shares up 2%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16953940-chembio-diagnostics-receives-fda-emergency-use-authorization-first-rapid-zika-igm-test\" target=\"_blank\">approves </a>Emergency Use Authorization &#40;EUA&#41; status in the U.S. for Chembio's (<a href='https://seekingalpha.com/symbol/CEMI' title='Chembio Diagnostics, Inc.'>CEMI</a> <font color='green'>+2.1%</font>) DPP Zika System, a rapid point-of-care test for the presumptive detection of Zika IgM antibodies in whole blood or serum.</li><li>The designation permits the use of the test during emergency circumstances. It is not yet FDA approved for routine use.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298204\" data-linked=\"FDA OKs emergency use of Chembio&#39;s rapid Zika test; shares up 2%\" data-tweet=\"$CEMI - FDA OKs emergency use of Chembio&#39;s rapid Zika test; shares up 2% https://seekingalpha.com/news/3298204-fda-oks-emergency-use-of-chembios-rapid-zika-test-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3298204-fda-oks-emergency-use-of-chembios-rapid-zika-test-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298203\" data-ts=\"1506611726\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAN\" target=\"_blank\">AAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298203-aarons-rallies-after-keybanc-nod\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aaron&#39;s rallies after Keybanc nod</a></h4><ul> <li>Aaron's (<a href='https://seekingalpha.com/symbol/AAN' title='Aaron&#39;s Inc.'>AAN</a> <font color='green'>+3.9%</font>) breaks higher after Keybanc upgrades the retailer to an Overweight rating.</li> <li>The investment firm's price target of $50 reps 20% upside for shares and is above the 52-week high for Aaron's.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3298203\" data-linked=\"Aaron&#39;s rallies after Keybanc nod\" data-tweet=\"$AAN - Aaron&#39;s rallies after Keybanc nod https://seekingalpha.com/news/3298203-aarons-rallies-after-keybanc-nod?source=tweet\" data-url=\"https://seekingalpha.com/news/3298203-aarons-rallies-after-keybanc-nod\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298199\" data-ts=\"1506611191\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FGP\" target=\"_blank\">FGP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298199-ferrellgas-partnersminus-4-following-large-quarterly-loss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ferrellgas Partners -4% following large quarterly loss</a></h4><ul>     <li>Ferrellgas Partners (<a href='https://seekingalpha.com/symbol/FGP' title='Ferrellgas Partners L.P'>FGP</a> <font color='red'>-4.4%</font>) plunges after reporting a larger than expected <a href=\"https://seekingalpha.com/news/3298085-ferrellgas-partners-misses-0_09-beats-revenue\" target=\"_blank\">FQ4 loss</a>, citing unusually warm weather during the period.</li>     <li>\"Weather for fiscal 2017 was a stunning 18% warmer than normal, and significantly affected our financial results,\" FGP says. \"Our strategy is to increase market share, as reflected in our  2% increase in retail gallons sold, exceeding those of prior year on an absolute and weather adjusted basis.\"</li>     <li>FGP says Q4 propane volumes sold totaled 791M gallons, up 1.5% Y/Y, but operating income generated by propane operations and related equipment sales was $188, down 8% Y/Y, citing customer mix and an increase in the overall wholesale cost of propane.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298199\" data-linked=\"Ferrellgas Partners -4% following large quarterly loss\" data-tweet=\"$FGP - Ferrellgas Partners -4% following large quarterly loss https://seekingalpha.com/news/3298199-ferrellgas-partnersminus-4-following-large-quarterly-loss?source=tweet\" data-url=\"https://seekingalpha.com/news/3298199-ferrellgas-partnersminus-4-following-large-quarterly-loss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298196\" data-ts=\"1506611072\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRVG\" target=\"_blank\">TRVG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298196-morgan-stanley-downgrades-trivago-on-increasing-headwinds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley downgrades Trivago on increasing headwinds</a></h4><ul><li>        Morgan Stanley <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Morgan+Stanley+Downgrades+trivago+N.V.+%28TRVG%29+to+Equalweight/13335964.html\" target=\"_blank\">downgrades</a> Trivago (NASDAQ:<a href='https://seekingalpha.com/symbol/TRVG' title='Trivago'>TRVG</a>) from Overweight to Equal Weight and drops the price target to $12.</li><li>               Analyst Brian Nowak cites multiple headwinds coming on and thinks online travel agents have started spending less on Trivago, which gives the company less money to grow.&nbsp;</li><li>               Nowak sees 2H18 as a tough comp period with limited upsides.&nbsp;</li><li>               Trivago shares are&nbsp;<font color='red'>down 2.19%</font>. &nbsp;&nbsp; </li><li>Competitor TripAdvisor (NASDAQ:<a href='https://seekingalpha.com/symbol/TRIP' title='TripAdvisor Inc.'>TRIP</a>) goes along for the ride with shares&nbsp;<font color='red'>down 1.22%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298196\" data-linked=\"Morgan Stanley downgrades Trivago on increasing headwinds\" data-tweet=\"$TRVG $TRVG $TRIP - Morgan Stanley downgrades Trivago on increasing headwinds https://seekingalpha.com/news/3298196-morgan-stanley-downgrades-trivago-on-increasing-headwinds?source=tweet\" data-url=\"https://seekingalpha.com/news/3298196-morgan-stanley-downgrades-trivago-on-increasing-headwinds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298162\" data-ts=\"1506610870\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298162-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a> <font color='green'>+66%</font>. <a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/MDGL' title='Madrigal Pharmaceuticals, Inc.'>MDGL</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals'>SYRS</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a> <font color='red'>-36%</font>. <a href='https://seekingalpha.com/symbol/ANGO' title='AngioDynamics, Inc.'>ANGO</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298162\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$ZYNE $SPPI $MDGL - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3298162-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3298162-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298183\" data-ts=\"1506610518\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298183-valeant-slumps-on-disclosure-of-filing-for-financing-transaction-shares-down-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeant slumps on disclosure of filing for financing transaction; shares down 5%</a></h4><ul><li>Valeant Pharmaceuticals (VRX <font color='red'>-5.4%</font>) slips on average volume on the heels of its announced filing with Canadian authorities ahead of a possible capital raise. The company says it is a routine filing and does not necessarily mean that it will pursue a private transaction.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298077-valeant-files-potential-private-financing\" target=\"_blank\">Valeant files for potential private financing</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298183\" data-linked=\"Valeant slumps on disclosure of filing for financing transaction; shares down 5%\" data-tweet=\"$BHC - Valeant slumps on disclosure of filing for financing transaction; shares down 5% https://seekingalpha.com/news/3298183-valeant-slumps-on-disclosure-of-filing-for-financing-transaction-shares-down-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3298183-valeant-slumps-on-disclosure-of-filing-for-financing-transaction-shares-down-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>75&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298192\" data-ts=\"1506610407\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIMX\" target=\"_blank\">HIMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298192-lake-street-upgrades-himax-on-growth-potential\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lake Street upgrades Himax on growth potential</a></h4><ul><li>        Lake Street Capital Markets <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Lake+Street+Capital+Markets+Upgrades+Himax+Technologies+%28HIMX%29+to+Buy/13337015.html\" target=\"_blank\">upgrades</a> Himax Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a>) from Hold to Buy with a $13 price target.</li><li>               Analyst Jaeson Schmidt cites confidence in core business growth opportunities following a management meeting. Schmidt has the most optimism about the 3D sensor market with its potential to transform Himax if it increases market size and ASPs.&nbsp;</li><li>               Himax shares are&nbsp;<font color='green'>up 1.74%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298192\" data-linked=\"Lake Street upgrades Himax on growth potential\" data-tweet=\"$HIMX - Lake Street upgrades Himax on growth potential https://seekingalpha.com/news/3298192-lake-street-upgrades-himax-on-growth-potential?source=tweet\" data-url=\"https://seekingalpha.com/news/3298192-lake-street-upgrades-himax-on-growth-potential\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>121&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298188\" data-ts=\"1506610126\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKU\" target=\"_blank\">ROKU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298188-roku-up-28-from-ipo-price-begins-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku up 28% from IPO price as it begins trading</a></h4><ul>   <li>Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a>) has opened for trading following its initial public offering, and is currently at $17.78, <font color='green'>up 28%</font> from its IPO price.</li>    <li>The streaming media company <a href=\"https://seekingalpha.com/news/3298042-roku-prices-ipo-14-high-end-range-1_3b-valuation\" target=\"_blank\">priced at $14</a> last night, the high end of its range, and raised about $220M for a valuation of $1.3B.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298188\" data-linked=\"Roku up 28% from IPO price as it begins trading\" data-tweet=\"$ROKU - Roku up 28% from IPO price as it begins trading https://seekingalpha.com/news/3298188-roku-up-28-from-ipo-price-begins-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3298188-roku-up-28-from-ipo-price-begins-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298182\" data-ts=\"1506609009\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298182-eia-natural-gas-inventory\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EIA Natural Gas Inventory</a></h4><ul>     <li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory: </a>&nbsp;<strong>+58 Bcf</strong> vs. +66 Bcf consensus, +97 Bcf last week.</li>     <li>Futures&nbsp;<font color='red'>-0.85%</font>&nbsp;to $3.035.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>,<a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298182\" data-linked=\"EIA Natural Gas Inventory\" data-tweet=\"$UNG $DGAZ $UGAZ - EIA Natural Gas Inventory https://seekingalpha.com/news/3298182-eia-natural-gas-inventory?source=tweet\" data-url=\"https://seekingalpha.com/news/3298182-eia-natural-gas-inventory\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298181\" data-ts=\"1506608890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXCM\" target=\"_blank\">DXCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298181-wedbush-defends-bullish-view-on-dexcom-after-fda-ok-of-abbotts-freestyle-libre\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wedbush defends bullish view on Dexcom after FDA OK of Abbott&#39;s FreeStyle Libre</a></h4><ul><li>Although it trimmed its price target to $76 (73% upside) from $85, Wedbush rushes to defend its Outperform rating on Dexcom (<a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a> <font color='red'>-35.5%</font>), down big after the FDA <a href=\"https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm577890.htm\" target=\"_blank\">approved </a>competitor Abbott's (<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a> <font color='green'>+4.4%</font>) FreeStyle Libre Flash Glucose Monitoring System, the first such device that does not requires a finger-stick blood sample for calibration.</li><li>Wedbush says the U.S. market opportunity is large enough (current penetration is only 25% in type 1diabetics) to accommodate more than one player, adding that Dexcom could accelerate its own no-calibration continuous glucose monitor and earn regulatory approval by the end of next year (this appears overly bullish since the one-calibration/day G6 device will probably not be approved until late H2 2018).</li><li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298037-abbott-labs-plus-3_5-percent-fda-oks-blood-glucose-monitoring-device\" target=\"_blank\">Abbott Labs +3.5% after FDA OKs blood glucose monitoring device</a> (Sept. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298181\" data-linked=\"Wedbush defends bullish view on Dexcom after FDA OK of Abbott&#39;s FreeStyle Libre\" data-tweet=\"$DXCM $DXCM $ABT - Wedbush defends bullish view on Dexcom after FDA OK of Abbott&#39;s FreeStyle Libre https://seekingalpha.com/news/3298181-wedbush-defends-bullish-view-on-dexcom-after-fda-ok-of-abbotts-freestyle-libre?source=tweet\" data-url=\"https://seekingalpha.com/news/3298181-wedbush-defends-bullish-view-on-dexcom-after-fda-ok-of-abbotts-freestyle-libre\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298169\" data-ts=\"1506606918\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WMC\" target=\"_blank\">WMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298169-western-asset-mortgage-down-2_3-after-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Western Asset Mortgage down 2.3% after capital raise</a></h4><ul><li>The company sold $100M of 6.75% convertible notes due in 2022. The conversion rate will initially equal 83.1947 shares of common stock per $1K principal amount of notes - equivalent to $12.02 per share, or roughly a 10% premium to last night's close.</li><li><a href='https://seekingalpha.com/symbol/WMC' title='Western Asset Mortgage Capital Corporation'>WMC</a>&nbsp;<font color='red'>-2.3%</font>&nbsp;to $10.68</li><li>Source: <a href=\"https://seekingalpha.com/pr/16953552-western-asset-mortgage-capital-corporation-announces-pricing-100000-000-convertible-senior\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3298169\" data-linked=\"Western Asset Mortgage down 2.3% after capital raise\" data-tweet=\"$WMC - Western Asset Mortgage down 2.3% after capital raise https://seekingalpha.com/news/3298169-western-asset-mortgage-down-2_3-after-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3298169-western-asset-mortgage-down-2_3-after-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298168\" data-ts=\"1506606867\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAIN\" target=\"_blank\">HAIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298168-hain-celestialplus-4-amid-board-developments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hain Celestial +4% amid board developments</a></h4><ul> <li>Hain Celestial (NASDAQ:<a href='https://seekingalpha.com/symbol/HAIN' title='The Hain Celestial Group, Inc.'>HAIN</a>) is up <font color='green'>4.18%</font> in early trading after the company reached a deal with Engaged Capital on board seats and agreed to work with an adviser.</li> <li>Engaged Capital reports that it now holds a stake of 9.9% in Hain vs. 7.75% as of June 30.</li> <li><a href=\"https://seekingalpha.com/filing/3708904\" target=\"_blank\">SEC Form 8-K </a></li> <li>Meanwhile on CNBC, David Faber is reporting that Hain is not for sale despite the developments today.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298117-hain-celestial-said-work-board-deal-activist-investor\" target=\"_blank\">Hain Celestial said to work board deal with activist investor</a> (Sept. 28)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298168\" data-linked=\"Hain Celestial +4% amid board developments\" data-tweet=\"$HAIN - Hain Celestial +4% amid board developments https://seekingalpha.com/news/3298168-hain-celestialplus-4-amid-board-developments?source=tweet\" data-url=\"https://seekingalpha.com/news/3298168-hain-celestialplus-4-amid-board-developments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298165\" data-ts=\"1506606531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPPI\" target=\"_blank\">SPPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298165-spectrum-pharmas-lung-cancer-candidate-poziotinib-shows-encouraging-action-in-preclinical-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spectrum Pharma&#39;s lung cancer candidate poziotinib shows encouraging action in preclinical and clinical studies; shares ahead 8%</a></h4><ul><li>Spectrum Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='green'>+7.8%</font>) jumps out the gate on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16953578-spectrum-pharmaceuticals-highlights-poziotinib-data-lung-cancer-presented-oral-presentation\" target=\"_blank\">announcement </a>of preliminary positive results on lung cancer candidate poziotinib. The preclinical and clinical data will be presented in mid-October at the 18th International Association for the Study of Lung Cancer in Yokohama, Japan.</li><li>In vitro studies using non-small cell lung cancer &#40;NSCLC&#41; cell lines, patient-derived xenograft models and genetically engineered mouse models of exon 20 insertion showed poziotinib to be ~100x more potent than osimertinib (AstraZeneca's Tagrisso) and 40x more potent than afatinib (Boehringer Ingelheim's Gilotrif) against a common panel of EGFR exon 20 insertions. It also demonstrated ~65x greater potency against exon 20 insertions compared to EGFR T790M mutations (third-generation inhibitors, including osimertinib and Clovis' rociletinib, are less potent for exon 20 mutations versus T790M).</li><li>Preliminary Phase 2 results from eight platinum-resistant metastatic NSCLC patients with exon 20 insertion mutations showed three partial responders after three-to-eight weeks of treatment with once-daily poziotinib.</li><li>Poziotinib is a pan-HER inhibitor that blocks signaling through the epidermal growth factor receptor &#40;EGFR&#41; family of tyrosine-kinase receptors, including HER receptor mutations. Its mechanism of action restricts the proliferation of tumor cells that overexpress the receptors.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3254479-mid-stage-study-launched-assessing-spectrum-pharmas-poziotinib-certain-lung-cancer-patients\" target=\"_blank\">Mid-stage study launched assessing Spectrum Pharma's poziotinib in certain lung cancer patients</a> (March 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298165\" data-linked=\"Spectrum Pharma&#39;s lung cancer candidate poziotinib shows encouraging action in preclinical and clinical studies; shares ahead 8%\" data-tweet=\"$SPPI - Spectrum Pharma&#39;s lung cancer candidate poziotinib shows encouraging action in preclinical and clinical studies; shares ahead 8% https://seekingalpha.com/news/3298165-spectrum-pharmas-lung-cancer-candidate-poziotinib-shows-encouraging-action-in-preclinical-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3298165-spectrum-pharmas-lung-cancer-candidate-poziotinib-shows-encouraging-action-in-preclinical-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298154\" data-ts=\"1506605038\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QRTEA\" target=\"_blank\">QRTEA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298154-liberty-interactiveminus-4_8-citi-trims-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Liberty Interactive -4.8% as Citi trims to Sell</a></h4><ul>   <li>Liberty Interactive (QVCA) is <font color='red'>down 4.8%</font> in premarket action as Citi cuts the stock to Sell.</li>    <li>Bad debt expenses are climbing and the company's facing declining TV viewers for its QVC network, writes analyst Jason Bazinet, and it's historically used shipping and handling as a key profit source but now faces an environment where customers expect free S/H. That along will put 30 basis points of pressure on revenue growth.</li>    <li>Subscriber losses in pay TV adds another 30 points of pressure, he says, and last year bad debt hit levels last seen in the 2008-2009 recession. (h/t Bloomberg)</li>    <li>Bazinet cut his price target to $22 from $27, implying 9% downside to the shares.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298154\" data-linked=\"Liberty Interactive -4.8% as Citi trims to Sell\" data-tweet=\"$QRTEA $QRTEB - Liberty Interactive -4.8% as Citi trims to Sell https://seekingalpha.com/news/3298154-liberty-interactiveminus-4_8-citi-trims-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3298154-liberty-interactiveminus-4_8-citi-trims-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298152\" data-ts=\"1506604848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298152-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a> <font color='green'>+60%</font>&nbsp;on its lead candidate ZYN002 <a href=\"https://seekingalpha.com/news/3298091-zynerbas-lead-candidate-zyn002-successful-mid-stage-fragile-x-study-shares-ahead-96-percent\" target=\"_blank\">successful</a> in mid-stage Fragile X study.</li>     <li><a href='https://seekingalpha.com/symbol/EXA' title='Exa Corporation'>EXA</a> <font color='green'>+43%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3298147-dassault-systemes-buy-exa-corp-400m\" target=\"_blank\">acquired</a> by Dassault Systemes (<a href='https://seekingalpha.com/symbol/DASTY' title='Dassault Systemes SA ADR'>OTCPK:DASTY</a>).</li>     <li><a href='https://seekingalpha.com/symbol/AQMS' title='Aqua Metals'>AQMS</a> <font color='green'>+27%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='green'>+18%</font>.</li>     <li>ADHD <font color='green'>+10%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3298097-alcobra-merge-arcturus-therapeutics-stock-deal-shares-ahead-15-percent-premarket\" target=\"_blank\">merger</a> with Arcturus Therapeutics.</li>     <li><a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a> <font color='green'>+9%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/HAIN' title='The Hain Celestial Group, Inc.'>HAIN</a> <font color='green'>+6%</font>&nbsp;on board <a href=\"https://seekingalpha.com/news/3298117-hain-celestial-said-work-board-deal-activist-investor\" target=\"_blank\">deal</a> with activist investor.</li>     <li>BBRY <font color='green'>+6%</font>. on Q2 earning&nbsp;<a href=\"https://seekingalpha.com/news/3298082-blackberry-beats-0_05-beats-revenue\" target=\"_blank\">result</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298152\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$ZYNE $EXA $DASTY - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3298152-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3298152-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298151\" data-ts=\"1506604721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKAO\" target=\"_blank\">AKAO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298151-achaogen-nabs-18m-barda-contract-to-support-c-scape-development-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Achaogen nabs $18M BARDA contract to support C-Scape development; shares up 2% premarket</a></h4><ul><li>Achaogen (NASDAQ:<a href='https://seekingalpha.com/symbol/AKAO' title='Achaogen'>AKAO</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket, albeit on only 250 shares, on the heels of its <a href=\"https://seekingalpha.com/pr/16953795-achaogen-awarded-18-million-contract-barda-support-development-orally-administered\" target=\"_blank\">announcement </a>that HHS's Biomedical Advanced Research and Development Authority &#40;BARDA&#41; has awarded it an $18M contract to support the development of S-Scape for the treatment of serious bacterial infections caused by extended-spectrum beta-lactamase-producing <em>Enterobacteriaceae</em>.</li><li>The contract includes committed funding of $12M over a nine-month base period followed by option periods potentially valued at $6M.</li><li><a href=\"http://www.achaogen.com/cscape/\" target=\"_blank\">C-Scape</a> is an orally available beta-lactam/beta-lactamase inhibitor combination antibiotic. It is currently in Phase 1 development. If successful, a Phase 3 study will be launched in H1 2018 in patients with complicated urinary tract infections.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298151\" data-linked=\"Achaogen nabs $18M BARDA contract to support C-Scape development; shares up 2% premarket\" data-tweet=\"$AKAO - Achaogen nabs $18M BARDA contract to support C-Scape development; shares up 2% premarket https://seekingalpha.com/news/3298151-achaogen-nabs-18m-barda-contract-to-support-c-scape-development-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3298151-achaogen-nabs-18m-barda-contract-to-support-c-scape-development-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298150\" data-ts=\"1506604630\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298150-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a>&nbsp;<font color='red'>-30%</font>&nbsp;<a href=\"https://seekingalpha.com/news/3298037-abbott-labs-plus-3_5-percent-fda-oks-blood-glucose-monitoring-device\" target=\"_blank\">after</a> FDA approved Abbott's FreeStyle Libre Flash&nbsp;glucose monitoring device.</li><li><a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>&nbsp;<font color='red'>-10%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3298084-rite-aid-reports-q2-results\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/ATHM' title='Autohome Inc.'>ATHM</a> <font color='red'>-10%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16953535-autohome-inc-announces-management-change\" target=\"_blank\">announcing</a> management change.</li><li><a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports Inc.'>PIR</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3297997-pier-1-imports-beats-0_01-beats-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3298096-intra-cellular-therapies-prices-150m-public-offering-common-stock-shares-4-percent-premarket\" target=\"_blank\">pricing</a> $150M public offering of common stock.</li><li><a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a>&nbsp;<font color='red'>-9%</font>&nbsp;on short seller Citron <a href=\"https://seekingalpha.com/news/3297980-veritone-slides-citron-says-stock-70-percent-lower\" target=\"_blank\">stating</a> stock should trade at $20.</li><li><a href='https://seekingalpha.com/symbol/FOR' title='Forestar Group Inc.'>FOR</a> <font color='red'>-7%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3298150\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$DXCM $RAD $ATHM - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3298150-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3298150-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298149\" data-ts=\"1506604200\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSTK\" target=\"_blank\">OSTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298149-overstock-com-up-again-on-blockchain-pep\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Overstock.com up again on blockchain pep</a></h4><ul> <li>Overstock.com (NASDAQ:<a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>) breaks higher in early trading after D.A. Davidson lifts its price target to $36 from $28.</li> <li>Shares of Overstcock rose over 4% yesterday after the company announced plans to form a digital token exchange. In premarket action today they are <font color='green'>up another 2.76%</font> to $29.75.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3297894-overstock-com-pops-ico-buzz\" target=\"_blank\">Overstock.com pops off ICO buzz</a> (Sept. 27)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298149\" data-linked=\"Overstock.com up again on blockchain pep\" data-tweet=\"$OSTK - Overstock.com up again on blockchain pep https://seekingalpha.com/news/3298149-overstock-com-up-again-on-blockchain-pep?source=tweet\" data-url=\"https://seekingalpha.com/news/3298149-overstock-com-up-again-on-blockchain-pep\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298148\" data-ts=\"1506603986\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABEO\" target=\"_blank\">ABEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298148-abeona-teams-up-brammer-bio-to-manufacture-gene-therapy-abominus-102-shares-up-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abeona teams up with Brammer Bio to manufacture gene therapy ABO-102; shares up 4% premarket</a></h4><ul><li>Abeona Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a>) is up&nbsp;<font color='green'>4%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16953889-abeona-therapeutics-brammer-bio-announce-collaboration-commercial-translation-abominus-102\" target=\"_blank\">announcement </a>that it will engage Brammer Bio to assist with process development and clinical vector supply to support the scale-up and manufacture of gene therapy ABO-102.</li><li>The company will provide more details during its R&amp;D day in New York on October 11.</li><li>Separately, it announces the appointment of Phillip Maples, Ph.D., as VP of Therapeutic Development and Quality Management to oversee all cell therapy manufacturing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298148\" data-linked=\"Abeona teams up with Brammer Bio to manufacture gene therapy ABO-102; shares up 4% premarket\" data-tweet=\"$ABEO - Abeona teams up with Brammer Bio to manufacture gene therapy ABO-102; shares up 4% premarket https://seekingalpha.com/news/3298148-abeona-teams-up-brammer-bio-to-manufacture-gene-therapy-abominus-102-shares-up-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3298148-abeona-teams-up-brammer-bio-to-manufacture-gene-therapy-abominus-102-shares-up-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298147\" data-ts=\"1506603940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DASTY\" target=\"_blank\">DASTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298147-dassault-systemes-to-buy-exa-corp-for-400m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dassault Systemes to buy Exa Corp. for $400M</a></h4><ul><li>        Dassault Systemes (<a href='https://seekingalpha.com/symbol/DASTY' title='Dassault Systemes SA ADR'>OTCPK:DASTY</a>) will <a href=\"https://finance.yahoo.com/news/frances-dassault-systemes-buy-exa-055035365.html\" target=\"_blank\">buy</a>&nbsp;software company Exa Corp. &nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/EXA' title='Exa Corporation'>EXA</a>) for $24.25 per share or about $400M.</li><li>               The buyout price offers a 43% premium on Exa&rsquo;s closing price on Wednesday.&nbsp;</li><li>               Exa creates simulation software combining digital physics and turbulence modeling. Clients include BMW, Tesla, and Toyota.&nbsp;</li><li>               The transaction will close in Q4.&nbsp;</li><li>               Exa shares are&nbsp;<font color='green'>up 42.57%</font>&nbsp;premarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3298147\" data-linked=\"Dassault Systemes to buy Exa Corp. for $400M\" data-tweet=\"$DASTY $DASTY $EXA - Dassault Systemes to buy Exa Corp. for $400M https://seekingalpha.com/news/3298147-dassault-systemes-to-buy-exa-corp-for-400m?source=tweet\" data-url=\"https://seekingalpha.com/news/3298147-dassault-systemes-to-buy-exa-corp-for-400m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298144\" data-ts=\"1506603783\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PM\" target=\"_blank\">PM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298144-goldman-sachs-calls-iqos-game-changer-for-philip-morris\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs calls IQOS a game changer for Philip Morris</a></h4><ul> <li>Goldman Sachs upgrades Philip Morris International (NYSE:<a href='https://seekingalpha.com/symbol/PM' title='Philip Morris International Inc.'>PM</a>) to a Conviction Buy List rating, one notch above just a garden variety Buy rating.</li> <li>Analyst Judy Hong doesn't think the company is getting enough credit for the major product innovation story in play.</li> <li>The IQOS platform is called by the GS team a game changer in tobacco (Reminder: IQOS heats tobacco just enough to release a flavored nicotine-containing vapor but doesn't burn tobacco).</li> <li>Shares of Philip Morris are <font color='green'>up 1.06%</font> premarket to $112.79.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298144\" data-linked=\"Goldman Sachs calls IQOS a game changer for Philip Morris\" data-tweet=\"$PM - Goldman Sachs calls IQOS a game changer for Philip Morris https://seekingalpha.com/news/3298144-goldman-sachs-calls-iqos-game-changer-for-philip-morris?source=tweet\" data-url=\"https://seekingalpha.com/news/3298144-goldman-sachs-calls-iqos-game-changer-for-philip-morris\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298142\" data-ts=\"1506603549\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISR\" target=\"_blank\">ISR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298142-isoray-revenues-up-27-in-q4-shares-ahead-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IsoRay revenues up 27% in Q4; shares ahead 4% premarket</a></h4><ul><li>IsoRay (<a href='https://seekingalpha.com/symbol/ISR' title='IsoRay, Inc.'>ISR</a>) <a href=\"https://seekingalpha.com/pr/16953728-isoray-announces-fourth-quarter-fiscal-2017-revenue-1_37-million-22-percent-fourth-quarter\" target=\"_blank\">Q4 results</a>: Revenues: $1.4M (+27.3%); R&amp;D Expense: $0.3M; SG&amp;A: $2M (+33.3%); Net Loss: ($1.9M) (-58.3%); Loss Per Share: ($0.03) (-50.0%); Quick Assets: $36.6M (+28.9%).</li><li>No guidance given.</li><li>Shares are up&nbsp;<font color='green'>4%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298142\" data-linked=\"IsoRay revenues up 27% in Q4; shares ahead 4% premarket\" data-tweet=\"$ISR - IsoRay revenues up 27% in Q4; shares ahead 4% premarket https://seekingalpha.com/news/3298142-isoray-revenues-up-27-in-q4-shares-ahead-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3298142-isoray-revenues-up-27-in-q4-shares-ahead-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298141\" data-ts=\"1506603271\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTGN\" target=\"_blank\">VTGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298141-vistagen-nabs-u-s-patent-covering-lead-candidate-avminus-101-shares-ahead-12-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VistaGen nabs U.S. patent covering lead candidate AV-101; shares ahead 12% premarket</a></h4><ul><li>Thinly traded nano cap VistaGen (NASDAQ:<a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a>) perks up&nbsp;<font color='green'>12%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16953697-vistagen-receives-notice-allowance-u-s-patent-trademark-office-u-s-patent-regarding-methods\" target=\"_blank\">announcement </a>that it received a Notice of Allowance from the USPTO for its patent application No. 14/775,287 related to certain methods of production for lead candidate AV-101.</li><li><a href=\"http://www.vistagen.com/?page_id=11\" target=\"_blank\">AV-101</a>&nbsp;is an orally available CNS prodrug that is converted in the brain by cells called&nbsp;<a href=\"https://en.wikipedia.org/wiki/Astrocyte\" target=\"_blank\">astrocytes&nbsp;</a>into its active metabolite, 7-chlorokynurenic acid (7-CI-KYNA), a highly selective antagonist of certain receptors &#40;NMDA&#41;&nbsp;that play key roles in neurodegenerative diseases, epilepsy and neuropathic pain.</li><li>It is currently in Phase 2 development for major depressive disorder and is ready to enter Phase 2 development for neuropathic pain.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298141\" data-linked=\"VistaGen nabs U.S. patent covering lead candidate AV-101; shares ahead 12% premarket\" data-tweet=\"$VTGN - VistaGen nabs U.S. patent covering lead candidate AV-101; shares ahead 12% premarket https://seekingalpha.com/news/3298141-vistagen-nabs-u-s-patent-covering-lead-candidate-avminus-101-shares-ahead-12-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3298141-vistagen-nabs-u-s-patent-covering-lead-candidate-avminus-101-shares-ahead-12-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298134\" data-ts=\"1506602606\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLS\" target=\"_blank\">SLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298134-galena-biopharma-completes-enrollment-in-two-neuvax-clinical-trials-in-combination\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galena Biopharma completes enrollment in two NeuVax clinical trials in combination with trastuzumab; shares ahead 10% premarket</a></h4><ul><li>Galena Biopharma (GALE) <a href=\"https://seekingalpha.com/pr/16953631-galena-biopharma-announces-completion-enrollment-two-neuvax-nelipepimut-s-clinical-trials\" target=\"_blank\">announces</a> that two clinical trials evaluating <a href=\"https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/default.aspx\" target=\"_blank\">NeuVax</a> (nelipepimut-S) in combination with <a href=\"https://en.wikipedia.org/wiki/Trastuzumab\" target=\"_blank\">trastuzumab</a> (Herceptin; Genentech/Roche) for the prevention of recurrence in breast cancer patients have completed patient enrollment.</li><li>The milestones were reported by the clinical research organization conducting both trials &ndash; a Phase 2b clinical trial in HER2 1+/2+ patients and a Phase 2 clinical trial in HER2 3+ patients enrolling 300 and 100 patients respectively.</li>     <li>The primary endpoint of both the studies is disease-free survival after 24 months, with results expected in Q4 2019.</li>          <li>NeuVax (nelipepimut-S) is a, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting.</li><li>Shares are up&nbsp;<font color='green'>10%</font>&nbsp;premarket on average volume.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3298134\" data-linked=\"Galena Biopharma completes enrollment in two NeuVax clinical trials in combination with trastuzumab; shares ahead 10% premarket\" data-tweet=\"$SLS - Galena Biopharma completes enrollment in two NeuVax clinical trials in combination with trastuzumab; shares ahead 10% premarket https://seekingalpha.com/news/3298134-galena-biopharma-completes-enrollment-in-two-neuvax-clinical-trials-in-combination?source=tweet\" data-url=\"https://seekingalpha.com/news/3298134-galena-biopharma-completes-enrollment-in-two-neuvax-clinical-trials-in-combination\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298133\" data-ts=\"1506602137\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABBV\" target=\"_blank\">ABBV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298133-abbvie-and-amgen-settle-humira-patent-dispute\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AbbVie and Amgen settle Humira patent dispute</a></h4><ul><li>AbbVie (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) and Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) have <a href=\"https://seekingalpha.com/pr/16953773-abbvie-announces-global-resolution-humira-adalimumab-patent-disputes-amgen\" target=\"_blank\">agreed to settle</a> their litigation over the latter's planned biosimilar to HUMIRA (adalimumab). Under the terms of the settlement, AbbVie will grant Amgen a non-exclusive license to HUMIRA intellectual property beginning on January 31, 2023 in the U.S. and on October 16, 2018 in most countries in the European Union. Other dates apply in a range of countries where AbbVie has patents. Amgen will pay royalties to AbbVie on sales of its biosimilar.</li><li>Specific terms are not disclosed. All litigation has been dismissed and Amgen has acknowledged the validity of AbbVie's HUMIRA patents.</li><li>ABBV is up&nbsp;<font color='green'>1%</font>&nbsp;premarket. AMGN is unchanged.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298133\" data-linked=\"AbbVie and Amgen settle Humira patent dispute\" data-tweet=\"$ABBV $ABBV $AMGN - AbbVie and Amgen settle Humira patent dispute https://seekingalpha.com/news/3298133-abbvie-and-amgen-settle-humira-patent-dispute?source=tweet\" data-url=\"https://seekingalpha.com/news/3298133-abbvie-and-amgen-settle-humira-patent-dispute\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298130\" data-ts=\"1506601986\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACN\" target=\"_blank\">ACN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298130-accenture-down-despite-q4-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Accenture down despite Q4 beats</a></h4><ul><li>           Accenture (NYSE:<a href='https://seekingalpha.com/symbol/ACN' title='Accenture plc'>ACN</a>) shares are&nbsp;<font color='red'>down 1.38%</font>&nbsp;premarket despite reporting Q4 revenue and EPS beats. The Q1 outlook put revenue between $9.1B and $9.35B compared to the $9.13B consensus estimate. </li><li> Revenue by operating group: Communications, Media &amp; Technology, $1.82B (+7% Y/Y); Financial Services, $1.95B (+9%); Health &amp; Public Service, $1.61B (+5%); Products, $2.49B (+10%); Resources, $1.26B (+5%). </li><li>           Revenue by region: North America, $4.23B (+4%); Europe, $3.12B (+10%); Growth Markets, $1.8B (+14%). &nbsp;&nbsp;   </li><li>        Financials: Operating margin was 14.2%, up 10 basis points on the year, with the FY18 outlook predicting between 14.9% to 15.1%. Operating cash flow was $1.9B, down from $2.07B, with $5B to $5.3B predicted for the year. Accenture reported $191M in property and equipment additions this quarter and expects the amount to total $600M for FY18. FCF totaled $1.8B, down from $1.91B in the prior year&rsquo;s quarter, with between $4.4B to $4.7B FCF expected in the fiscal year.</li><li>               Bookings: New bookings totaled $10.1B with Consulting new bookings at $5.1B and Outsourcing new bookings at $5B.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16953573-accenture-reports-strong-fourth-quarter-full-year-fiscal-2017-results\" target=\"_blank\">Press release</a>&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298083-accenture-beats-0_01-beats-revenue\" target=\"_blank\">Accenture beats by $0.01, beats on revenue</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298130\" data-linked=\"Accenture down despite Q4 beats\" data-tweet=\"$ACN - Accenture down despite Q4 beats https://seekingalpha.com/news/3298130-accenture-down-despite-q4-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3298130-accenture-down-despite-q4-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298126\" data-ts=\"1506601466\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DEST\" target=\"_blank\">DEST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298126-orchestra-premaman-takes-swing-destination-maternity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Orchestra-Prémaman takes a swing at Destination Maternity</a></h4><ul>         <li>Orchestra-Pr&eacute;maman S.A. issues a letter to shareholders of Destination Maternity (NASDAQ:<a href='https://seekingalpha.com/symbol/DEST' title='Destination Maternity Corporation'>DEST</a>) in opposition of the company's board nominees.</li>     <li>Orchesta says the directors nominated by the retailer have underperformed during their tenure and repeatedly missed important targets while reporting financial information in an \"unclear\" way.</li><li>Orchesta holds a stake of 13.8% in Destination Maternity.</li><li>Shares of Destination Maternity are down 69% YTD.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/16949403-orchestra-premaman-s-issues-stop-look-listen-letter-shareholders-destination-maternity\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3298126\" data-linked=\"Orchestra-Prémaman takes a swing at Destination Maternity\" data-tweet=\"$DEST - Orchestra-Prémaman takes a swing at Destination Maternity https://seekingalpha.com/news/3298126-orchestra-premaman-takes-swing-destination-maternity?source=tweet\" data-url=\"https://seekingalpha.com/news/3298126-orchestra-premaman-takes-swing-destination-maternity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298125\" data-ts=\"1506601434\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDHL\" target=\"_blank\">RDHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298125-redhill-up-5-premarket-ahead-of-data-release-from-mid-stage-study-of-bekinda-in-ibs-d\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RedHill up 5% premarket ahead of data release from mid-stage study of Bekinda in IBS-D</a></h4><ul><li>Thinly traded micro cap RedHill Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/RDHL' title='RedHill Biopharma Ltd.'>RDHL</a>) is up&nbsp;<font color='green'>5%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16953593-redhill-biopharma-announce-top-line-results-bekinda-12-mg-phase-ii-study-ibs-d-october-3rd\" target=\"_blank\">announcement </a>that, on October 3, it will report top-line data from its Phase 2 clinical trial assessing BEKINDA (ondansetron) 12 mg (RHB-102) for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).</li><li>Management will host a conference call at 9:00 am ET on October 3 to discuss the results.</li><li>Positive results from a Phase 3 study assessing a 24 mg dose of BEKINDA in acute gastroenteritis and gastritis were announced in June.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3273427-redhills-bekinda-successful-late-stage-gastroenteritis-study-shares-ahead-7-percent-premarket\" target=\"_blank\">RedHill's Bekinda successful in late-stage gastroenteritis study; shares ahead 7% premarket</a> (June 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298125\" data-linked=\"RedHill up 5% premarket ahead of data release from mid-stage study of Bekinda in IBS-D\" data-tweet=\"$RDHL - RedHill up 5% premarket ahead of data release from mid-stage study of Bekinda in IBS-D https://seekingalpha.com/news/3298125-redhill-up-5-premarket-ahead-of-data-release-from-mid-stage-study-of-bekinda-in-ibs-d?source=tweet\" data-url=\"https://seekingalpha.com/news/3298125-redhill-up-5-premarket-ahead-of-data-release-from-mid-stage-study-of-bekinda-in-ibs-d\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298111\" data-ts=\"1506600771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENDP\" target=\"_blank\">ENDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298111-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Endo International (NASDAQ:<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a>) initiated with Sell rating with a $7 (22% downside risk) by Goldman Sachs. Shares down&nbsp;<font color='red'>2%</font>&nbsp;premarket.</li><li>Oxford Immunotec (NASDAQ:<a href='https://seekingalpha.com/symbol/OXFD' title='Oxford Immunotec Global PLC'>OXFD</a>) initiated with Buy rating and $21 (25% upside) price target by BTIG Research.</li><li>Pacira Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PCRX' title='Pacira Pharmaceuticals, Inc.'>PCRX</a>) initiated with Neutral rating and $41 (4% upside) price target by Goldman.</li><li>MediWound (NASDAQ:<a href='https://seekingalpha.com/symbol/MDWD' title='Mediwound Ltd.'>MDWD</a>) initiated with Outperform rating and $9 (84% upside) price target by Cowen and Company.</li><li>Momenta Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a>) initiated with Neutral rating and $18 (flat) price target by Goldman.</li><li>Mallinckrodt (NYSE:<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a>) initiated with Buy rating and $55 (55% upside) price target by Goldman. Shares up&nbsp;<font color='green'>3%</font>&nbsp;premarket.</li><li>Impax Laboratories (IPXL) initiated with Neutral rating and $20 (13% downside risk) price target by Goldman.</li><li>Jazz Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/JAZZ' title='Jazz Pharmaceuticals, Inc.'>JAZZ</a>) initiated with Neutral rating and $165 (11% upside) price target by Goldman.</li><li>Horizon Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/HZNP' title='Horizon Pharma plc'>HZNP</a>) initiated with Buy rating and $16 (29% upside) price target by Goldman. Shares up&nbsp;<font color='green'>3%</font>&nbsp;premarket.</li><li>Syros Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals'>SYRS</a>) upgraded to Outperform by JMP Securities.</li><li>Dexcom (NASDAQ:<a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a>) downgraded to Market Perform by Raymond James and Neutral by JPMorgan after FDA approval of Abbott's FreeStyle Libre Flash. Shares down&nbsp;<font color='red'>27%</font>&nbsp;premarket.</li><li>Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) price target raised to $198 from $183 by Mizuho citing optimism that it will prevail over Regeneron/Sanofi in the Repatha/Praluent litigation.</li><li>Check-Cap (NASDAQ:<a href='https://seekingalpha.com/symbol/CHEK' title='Check-Cap Ltd.'>CHEK</a>) price target raised to $7 (265% upside) from $6 by H.C. Wainwright on expectations of CE Mark for C-Scan.</li><li>Pacific Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/PACB' title='Pacific Biosciences of California'>PACB</a>) downgraded to Neutral by C.L. King.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298111\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$ENDP $ENDP $OXFD - Premarket analyst action - healthcare https://seekingalpha.com/news/3298111-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3298111-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298121\" data-ts=\"1506600656\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAD\" target=\"_blank\">RAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298121-rite-aid-revenues-off-4-in-q2-shares-off-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rite Aid revenues off 4% in Q2; shares off 3% premarket</a></h4><ul><li>Rite Aid (<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) <a href=\"https://seekingalpha.com/pr/16953584-rite-aid-reports-fiscal-2018-second-quarter-results\" target=\"_blank\">Q2 results</a>: Revenues: $7,678.9M (-4.4%); Net Income: $170.7M; EPS: $0.16; Non-GAAP Loss Per Share: ($0.01); Quick Assets: $239M (-2.6%); CF Ops: $205.1M.</li><li>No guidance given.</li><li>Shares are down&nbsp;<font color='red'>3%</font>&nbsp;premarket on modest volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298121\" data-linked=\"Rite Aid revenues off 4% in Q2; shares off 3% premarket\" data-tweet=\"$RAD - Rite Aid revenues off 4% in Q2; shares off 3% premarket https://seekingalpha.com/news/3298121-rite-aid-revenues-off-4-in-q2-shares-off-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3298121-rite-aid-revenues-off-4-in-q2-shares-off-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>176&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298119\" data-ts=\"1506600532\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298119-blackberry-up-8-after-q2-beats-and-positive-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackBerry up 8% after Q2 beats and positive guidance</a></h4><ul><li>        BlackBerry (BBRY) shares are&nbsp;<font color='green'>up 8.23%</font>&nbsp;premarket after reporting Q2 revenue and EPS beats. The company reported record adjusted software and services revenue of $196M.</li><li>               FY18 outlook: revenue, $920M to $950M (consensus: $919.53M); software and services revenue, 10% to 15% growth; FCF, positive after accounting for Qualcomm arbitration award net impact.&nbsp;</li><li>               Product and service revenue: Enterprise software and services, $102M (flat Y/Y); BlackBerry Technology Solutions, $38M (flat); Licensing, IP and other, $56M (+250%); Handheld devices, $16M (-85%); SAF, $37M (-59%).&nbsp;</li><li>               Customer retention: About 79% of software and services revenue was recurring and BlackBerry had around 3,300 enterprise customer orders in Q2.&nbsp;</li><li>               Financials: Gross margin was 76% non-GAAP or 74% GAAP compared to 29.3% in last year&rsquo;s quarter. Cash flow from operations totaled $3M. FCF broke even in Q2 and BlackBerry ended the quarter with $2.5B in cash and equivalents.&nbsp; &nbsp;&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16953625-blackberry-reports-record-software-services-revenue-fiscal-2018-second-quarter\" target=\"_blank\">Press release</a>&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3298082-blackberry-beats-0_05-beats-revenue\" target=\"_blank\">BlackBerry beats by $0.05, beats on revenue</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298119\" data-linked=\"BlackBerry up 8% after Q2 beats and positive guidance\" data-tweet=\"$BB - BlackBerry up 8% after Q2 beats and positive guidance https://seekingalpha.com/news/3298119-blackberry-up-8-after-q2-beats-and-positive-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3298119-blackberry-up-8-after-q2-beats-and-positive-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298117\" data-ts=\"1506600341\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAIN\" target=\"_blank\">HAIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298117-hain-celestial-said-to-work-board-deal-activist-investor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hain Celestial said to work board deal with activist investor</a></h4><ul>     <li>Hain Celestial (NASDAQ:<a href='https://seekingalpha.com/symbol/HAIN' title='The Hain Celestial Group, Inc.'>HAIN</a>) struck an agreement with activist investor Engaged Capital for board inclusion, according to The Wall Street Journal.</li>     <li>The company will nominate six new directors and three board members won&rsquo;t run for re-election per the reported terms of the deal.</li><li>Hain hasn't filed notification of its board plans yet.</li>     <li>The board development could open the door for the exploration of a sale of the company.</li>     <li>Shares of Hain are <font color='green'>up 3.88%</font> in premarket trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3298117\" data-linked=\"Hain Celestial said to work board deal with activist investor\" data-tweet=\"$HAIN - Hain Celestial said to work board deal with activist investor https://seekingalpha.com/news/3298117-hain-celestial-said-to-work-board-deal-activist-investor?source=tweet\" data-url=\"https://seekingalpha.com/news/3298117-hain-celestial-said-to-work-board-deal-activist-investor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298107\" data-ts=\"1506599900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAG\" target=\"_blank\">CAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298107-on-conagra-foods-q1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on ConAgra Foods&#39; Q1</a></h4><ul><li>ConAgra Foods (NYSE:<a href='https://seekingalpha.com/symbol/CAG' title='ConAgra Brands, Inc.'>CAG</a>) reports organic net sales declned 3% in <a href=\"https://seekingalpha.com/pr/16953643-conagra-brands-reports-strong-first-quarter\" target=\"_blank\">Q1</a>.</li><li>Segment net sales:&nbsp;Grocery &amp; Snacks: $746M (-1.5%);&nbsp;Refrigerated &amp; Frozen: $616M (+1.8%);&nbsp;International: $191M (-2%);&nbsp;Foodservice: $252M (-6.1%).</li><li>Adjusted gross margin rate improved 26 bps to 29.2% as higher price/mix and the impact of divesting lower margin businesses</li><li><b>FY2018 Guidance</b>: Net sales: -2% to flat; Organic net sales: -2% to flat;&nbsp;Adjusted operating margin rate: 15.9% to 16.3%; Tax rate: 32.5% to 33.5%; Adjusted EPS: $1.84 to $1.89.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298107\" data-linked=\"More on ConAgra Foods&#39; Q1\" data-tweet=\"$CAG - More on ConAgra Foods&#39; Q1 https://seekingalpha.com/news/3298107-on-conagra-foods-q1?source=tweet\" data-url=\"https://seekingalpha.com/news/3298107-on-conagra-foods-q1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298096\" data-ts=\"1506598415\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITCI\" target=\"_blank\">ITCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298096-intra-cellular-therapies-prices-150m-public-offering-of-common-stock-shares-off-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intra-Cellular therapies prices $150M public offering of common stock; shares off 4% premarket</a></h4><ul> <li>Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a>) <a href=\"https://seekingalpha.com/pr/16953420-intra-cellular-therapies-prices-150-million-public-offering-common-stock\" target=\"_blank\">prices</a> its previously announced public offering of 9.7M shares of common stock at a price of $15.50 per share. Net proceeds should be ~$140.6M.</li><li>Underwriters over-allotment is an additional&nbsp;1,451,613&nbsp;shares.</li>   <li>Closing date is October 2.</li><li>Shares are down&nbsp;<font color='red'>4%</font>&nbsp;premarket on modest volume. Yesterday's close was $16.66.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3298096\" data-linked=\"Intra-Cellular therapies prices $150M public offering of common stock; shares off 4% premarket\" data-tweet=\"$ITCI - Intra-Cellular therapies prices $150M public offering of common stock; shares off 4% premarket https://seekingalpha.com/news/3298096-intra-cellular-therapies-prices-150m-public-offering-of-common-stock-shares-off-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3298096-intra-cellular-therapies-prices-150m-public-offering-of-common-stock-shares-off-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298097\" data-ts=\"1506598269\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCT\" target=\"_blank\">ARCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298097-alcobra-to-merge-arcturus-therapeutics-in-all-stock-deal-shares-ahead-15-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alcobra to merge with Arcturus Therapeutics in all-stock deal; shares ahead 15% premarket</a></h4><ul><li>Thinly traded nano cap Alcobra (ADHD) is up&nbsp;<font color='green'>15%</font>&nbsp;premarket on light volume on the <a href=\"https://seekingalpha.com/pr/16953350-alcobra-ltd-arcturus-therapeutics-inc-agree-merge\" target=\"_blank\">news </a>that it has agreed to merge with privately held Arcturus Therapeutics in an all-stock transaction. The combined company will focus on developing RNA medicines to treat infectious diseases, cystic fibrosis, NASH and rare liver diseases.</li><li>Under the terms of the merger agreement, Alcobra shareholders will own ~40% of the combined firm while Arcturus shareholders will own ~60%. The deal should close in Q4.</li><li>The companies will host a conference call this morning at 8:30 am ET to discuss the merger.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298097\" data-linked=\"Alcobra to merge with Arcturus Therapeutics in all-stock deal; shares ahead 15% premarket\" data-tweet=\"$ARCT - Alcobra to merge with Arcturus Therapeutics in all-stock deal; shares ahead 15% premarket https://seekingalpha.com/news/3298097-alcobra-to-merge-arcturus-therapeutics-in-all-stock-deal-shares-ahead-15-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3298097-alcobra-to-merge-arcturus-therapeutics-in-all-stock-deal-shares-ahead-15-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298091\" data-ts=\"1506597602\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZYNE\" target=\"_blank\">ZYNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298091-zynerbas-lead-candidate-zyn002-successful-in-mid-stage-fragile-x-study-shares-ahead-96\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zynerba&#39;s lead candidate ZYN002 successful in mid-stage Fragile X study; shares ahead 96% premarket</a></h4><ul><li>Nano cap Zynerba Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a>) jumps&nbsp;<font color='green'>96%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16953550-zynerba-pharmaceuticals-announces-positive-top-line-results-zyn002-open-label-phase-2-fab-c\" target=\"_blank\">announcement </a>of positive results from an open-label exploratory Phase 2 clinical trial, FAB-C, assessing lead candidate ZYN002 (cannabidiol [CBD] gel) in pediatric and adolescent patients with <a href=\"https://ghr.nlm.nih.gov/condition/fragile-x-syndrome\" target=\"_blank\">Fragile X syndrome</a> &#40;FXS&#41;, an inherited autism-like disorder.</li><li>The 20-subject study met its primary endpoint of demonstrating a statistically significant 46% improvement from baseline at week 12 in a scale called ADAMS (p&lt;0.0001). Participants treated with ZYN002 also showed clinically meaningful improvements key behavioral characteristics such as temper tantrums, social avoidance, repetitive movements and hyperactivity.</li><li>ZYN002 was safe and well-tolerated. Two patients discontinued treatment due to worsening of pre-existing eczema. Four others experienced adverse events, none considered severe.</li><li>The company plans to meet with the FDA in H1 2018 with the aim of initiating a Phase 2/3 study as soon as feasible. ZYN002 has Orphan Drug status for the treatment of FXS.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3288886-zynerbas-lead-candidate-zyn002-flunks-mid-stage-study-osteoarthritis-associated-knee-pain\" target=\"_blank\">Zynerba's lead candidate ZYN002 flunks mid-stage study in osteoarthritis-associated knee pain; shares down 29% premarket</a> (Aug. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298091\" data-linked=\"Zynerba&#39;s lead candidate ZYN002 successful in mid-stage Fragile X study; shares ahead 96% premarket\" data-tweet=\"$ZYNE - Zynerba&#39;s lead candidate ZYN002 successful in mid-stage Fragile X study; shares ahead 96% premarket https://seekingalpha.com/news/3298091-zynerbas-lead-candidate-zyn002-successful-in-mid-stage-fragile-x-study-shares-ahead-96?source=tweet\" data-url=\"https://seekingalpha.com/news/3298091-zynerbas-lead-candidate-zyn002-successful-in-mid-stage-fragile-x-study-shares-ahead-96\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298089\" data-ts=\"1506597123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MKC\" target=\"_blank\">MKC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298089-on-mccormicks-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on McCormick&#39;s Q3</a></h4><ul><li>McCormick (NYSE:<a href='https://seekingalpha.com/symbol/MKC' title='McCormick & Company, Inc.'>MKC</a>)&nbsp;reports sales rose 8.4% on a constant currency basis in <a href=\"https://seekingalpha.com/pr/16953554-mccormick-reports-strong-sales-profit-growth-third-quarter-updates-2017-financial-outlook\" target=\"_blank\">Q3</a></li><li>Acquisition contributed 4 percentage point of growth in the quarter.</li><li>Segment revenue: Consumer: $696.8M (+5.3%, +4.6% on a constant currency basis); Industrial: $488.4M (+13.8%, +14.4% on a&nbsp;constant currency basis).</li><li>Gross margin rate slipped 70 bps to 40.9%.</li><li>Segment operating income: Consumer: $139.7M (+9.7%); Industrial: $64.1M (+43.1%).</li><li>Adjusted operating margin rate improved 140 bps to 17.2%.</li><li>Income from unconsolidated operations grew 1.2% to $8.2M.</li><li><b>FY2017 Guidance</b>:&nbsp;Sales: &nbsp;+9% to +10% (+10% to +11% in constant currency); Operating income: +10% to +11%; Adjusted operating income: +20% to +21%; Diluted EPS: $3.69 to $3.73; Adjusted diluted EPS: $4.20 to $4.24.</li></ul><div class=\"tiny-share-widget\" data-id=\"3298089\" data-linked=\"More on McCormick&#39;s Q3\" data-tweet=\"$MKC - More on McCormick&#39;s Q3 https://seekingalpha.com/news/3298089-on-mccormicks-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3298089-on-mccormicks-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298082\" data-ts=\"1506596531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298082-blackberry-beats-0_05-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackBerry beats by $0.05, beats on revenue</a></h4><ul><li>BlackBerry (BBRY): Q2 EPS of $0.05 <font color='green'>beats by $0.05</font>.</li><li>Revenue of $249M (-29.3% Y/Y) <font color='green'>beats by $29.09M</font>.</li><li>Shares <font color='green'>+9.3%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16953625-blackberry-reports-record-software-services-revenue-fiscal-2018-second-quarter'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3298082\" data-linked=\"BlackBerry beats by $0.05, beats on revenue\" data-tweet=\"$BB - BlackBerry beats by $0.05, beats on revenue https://seekingalpha.com/news/3298082-blackberry-beats-0_05-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3298082-blackberry-beats-0_05-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>102&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3298081\" data-ts=\"1506596453\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTCT\" target=\"_blank\">PTCT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3298081-trading-halted-in-ptc-therapeutics-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trading halted in PTC Therapeutics pending news</a></h4><ul><li>Nasdaq has suspended trading in PTC Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a>) pending the release of news. Today is the Ad Com review for DMD candidate Translarna (ataluren).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297574-investors-shaken-ptcs-briefing-docs-ahead-ad-com-dmd-candidate-translarna-shares-14-percent\" target=\"_blank\">Investors shaken by PTC's briefing docs ahead of Ad Com for DMD candidate Translarna; shares down 14% premarket</a> (Sept. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3298081\" data-linked=\"Trading halted in PTC Therapeutics pending news\" data-tweet=\"$PTCT - Trading halted in PTC Therapeutics pending news https://seekingalpha.com/news/3298081-trading-halted-in-ptc-therapeutics-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3298081-trading-halted-in-ptc-therapeutics-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":71,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}